Bicyclic amine carboxamide derivatives
By developing novel compounds that bind to orexin type 2 receptors, the problem of the ineffective treatment of orexin type 2 receptor-related diseases in existing technologies has been solved, achieving effective treatment and prevention of narcolepsy, idiopathic hypersomnia, and sleep apnea syndrome.
Patent Information
- Application Number
- CN202380035368.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-22
- Filing Date
- 2023-04-21
- Publication Date
- 2024-11-29
AI Technical Summary
Current technologies have not effectively addressed the treatment and prevention of diseases related to orexin type 2 receptors, such as narcolepsy, idiopathic hypersomnia, and sleep apnea syndrome.
A new class of compounds or their pharmaceutically acceptable salts have been developed that can bind to orexin type 2 receptors and have agonistic effects for the treatment and prevention of orexin type 2 receptor-related diseases.
These compounds have shown significant therapeutic effects on diseases such as narcolepsy, idiopathic hypersomnia, and sleep apnea syndrome, providing effective treatment and prevention methods.
Smart Images

Figure CN119053606A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a therapeutic or preventive drug for diseases related to orexin receptors, particularly orexin type 2 receptors, containing a novel compound having a fused ring skeleton or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, it relates to a therapeutic or preventive drug for diseases such as narcolepsy, idiopathic hypersomnia, hypersomnia, and sleep apnea syndrome. Background Art
[0002] Orexin is a neuropeptide specifically produced in specific nerve cells distributed in the lateral hypothalamus and its surrounding areas. Orexin is an endogenous ligand of the orexin receptor, a G protein-coupled receptor mainly present in the brain, and binds to the orexin receptor. Regarding orexin receptors, two subtypes, type 1 and type 2, are known (Non-Patent Document 1).
[0003] It has been reported that narcolepsy-like symptoms produced in transgenic mice with modified orexin neurons were improved by intracerebroventricular administration of orexin peptides (Non-Patent Document 2), and it has also been reported that narcolepsy-like symptoms were induced by knockout (KO) of orexin precursor, a precursor protein of orexin (Non-Patent Document 3). Furthermore, it has been clarified that the orexin concentration in the cerebrospinal fluid of narcolepsy patients is significantly reduced (Non-Patent Document 4), suggesting that narcolepsy is caused by a lack of orexin.
[0004] In addition, a mutation of orexin type 2 receptor in dogs with hereditary narcolepsy was reported (non-patent document 5), suggesting that orexin type 2 receptor is related to sleep-wakefulness, and furthermore, it was clarified that orexin type 2 receptor KO mice also cause narcolepsy-like symptoms (non-patent document 6), suggesting that orexin type 2 receptor stimulation is closely related to wakefulness-maintaining effects. Based on this background, orexin type 2 receptor agonists are expected to be promising therapeutic drugs for diseases presenting excessive sleep symptoms, such as narcolepsy.
[0005] In recent years, compounds having orexin type 2 receptor agonistic activity have been reported (Patent Documents 1 or 2).
[0006] Prior art literature
[0007] Patent Literature
[0008] Patent document 1: International Publication No. 2017 / 135306;
[0009] Patent document 2: International Publication No. 2021 / 107023;
[0010] Non-patent literature
[0011] Non-patent document 1: Cell, Vol. 92, pp. 573-585, 1998;
[0012] Non-patent document 2: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, pp. 4649-4654, 2004 (Proc. Natl. Acad. Sci. USA, Vol. 101, pp. 4649-4654, 2004);
[0013] Non-patent document 3: Cell, Vol. 98, pp. 437-451, 1999;
[0014] Non-patent document 4: THELANCET, Vol. 355, pp. 39-40, 2000;
[0015] Non-patent document 5: Cell, Vol. 98, pp. 365-376, 1999 (Cell, Vol. 98, pp. 365-376, 1999);
[0016] Non-patent document 6: Neuron, Vol. 38, pp. 715-730, 2003;
[0017] Non-patent document 7: Brain, Vol. 130, pp. 1577-1585, 2007;
[0018] Non-patent document 8: Neuroscience Letters, Vol. 569, pp. 68-73, 2014. Summary of the invention
[0019] Problems to be solved by the invention
[0020] An object of the present invention is to provide a therapeutic or preventive drug for diseases associated with orexin type 2 receptor, specifically, narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, and the like.
[0021] Means for solving problems
[0022] The present inventors have conducted intensive studies and have found that a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof (hereinafter sometimes referred to as "the compound of the present invention") has therapeutic and preventive effects on diseases associated with orexin type 2 receptor, specifically, narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, and the like, thereby completing the present invention.
[0023] That is, the present invention is as follows.
[0024] [Item 1]
[0025] A compound represented by formula (1) or a pharmaceutically acceptable salt thereof,
[0026] [Chemical formula 1]
[0027]
[0028] In the formula,
[0029] R 1 and R 2 each independently represents a hydrogen atom, a halogen atom, a cyano group, -(=O)NR 3 R 4 , carboxyl, -(C=O)OR 5 , C that can be replaced 1-4 Alkyl or substituted C 1-4 Alkoxy, in addition, R 1 and R 2 If chemically possible, they can bond to the same carbon atom. 1 and R 2 When the carbon atoms on the ring are bonded to different carbon atoms, they can be bonded to each other through C 1-6 Alkylene groups are bonded to form condensed rings or bridged rings;
[0030] R 3 and R 4 Each independently represents a hydrogen atom or a substitutable C 1-4 alkyl;
[0031] R 5 Indicates a replaceable C 1-4 alkyl;
[0032] -L 1 -Ring G represents -Ring G, -CH2-Ring G (the CH2 may be replaced by one or more identical or different C 1-6 Alkyl substituted), -NR 6 -Ring G, -C(=O)-Ring G, -OC(=O)-Ring G, -SO-Ring G, -SO2-Ring G, -S-Ring G or -O-Ring G;
[0033] R 6 Represents a hydrogen atom or a replaceable C 1-4 alkyl;
[0034] n is an integer of 1 or 2;
[0035] Ring G represents a C which may be substituted 6-10 Aromatic carbocyclic group, 5-10 membered aromatic heterocyclic group which may be substituted, C 3-6 A saturated carbocyclic group or a 4- to 10-membered saturated heterocyclic group which may be substituted;
[0036] A 1 represents an oxygen atom or a sulfur atom;
[0037] A 2 represents an oxygen atom or -NH-;
[0038] j, k, l and m are each independently an integer of 0, 1 or 2;
[0039] The dashed line represents a single bond or a double bond;
[0040] X stands for -CR 7 -, nitrogen atom or carbon atom;
[0041] R 7 represents a hydrogen atom, a hydroxyl group, a halogen atom, a cyano group, or a substituted C 1-4 alkyl;
[0042] Ring E represents the following formula (1a-1), (1a-2) or (1a-3):
[0043] [Chemical formula 2]
[0044]
[0045] In the formula,
[0046] X 1 ~X 8 Each independently represents a nitrogen atom or -CR a4 -;
[0047] Q 1 and Q 2 Represents oxygen atom or -NR a5 -;
[0048] R a1 ~R a5 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 6-10 Aromatic carbocyclic group (the C 6-10The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), cyano, C 1-4 Alkoxy (the alkoxy group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl, C 1-4 substituted with an alkoxy group) or a 5- to 10-membered aromatic heterocyclic group, and R a2 and R a3 If chemically possible, they can be bonded to the same carbon atom; 1 and X 3 All CR a4 In the case of 2 R a4 Together with the carbon atoms to which they are bonded, they can form 1 , X 2 and X 3 The 5-membered ring is condensed to form a 6-membered carbon ring.
[0049] [Item 2]
[0050] The compound of item 1 or a pharmaceutically acceptable salt thereof, wherein
[0051] R 1 ~R 7 The "C that can be replaced 1-4 The substituents in the "alkyl" are each independently 1 or 2 or more of the same or different halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl, "C 1-4 The substituents in the "alkoxy" are each independently 1 or 2 or more halogen atoms, hydroxyl groups or C 3-7 Cycloalkyl,
[0052] Ring G C 6-10 Aromatic carbocyclic group, 5-10 membered aromatic heterocyclic group, C 3-6 The substituents which may be substituted in the saturated carbocyclic group and the 4- to 10-membered saturated heterocyclic group are each independently selected from halogen atoms, C 1-6Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substituted), C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-7 Cycloalkyl substituted), C 1-4 Alkoxy (the alkoxy group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 3-7 Cycloalkyl substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-7 Cycloalkyl substituted) and C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-7 cycloalkyl) or, if there are multiple substituents, two of them may be C 1-6 The alkylene groups are bonded to form any chemically possible bicyclic structure in a fused ring, a spiro ring or a bridged ring.
[0053] [Item 3]
[0054] The compound or pharmaceutically acceptable salt thereof according to any one of item 1 or 2, wherein
[0055] R 1 ~R 7 The "C that can be replaced 1-4 The substituents in the "alkyl" are each independently 1 or 2 or more halogen atoms or C 1-4 Alkoxy, "substituted C 1-4 The substituents in the "alkoxy" group are each independently 1 or 2 or more halogen atoms which are the same or different,
[0056] Ring G C 6-10 Aromatic carbocyclic group, 5-10 membered aromatic heterocyclic group, C 3-6 The substituents which may be substituted in the saturated carbocyclic group and the 4- to 10-membered saturated heterocyclic group are each independently selected from halogen atoms, C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted), C 6-10 Aromatic carbocyclic group (the C6-10 The aromatic carbocyclic group may be substituted with 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms which are the same or different), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted) and C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 substituted with alkoxy) or, in the case of having multiple substituents, two of which may be C 1-6 The alkylene groups are bonded to form any chemically possible bicyclic structure in a fused ring, a spiro ring or a bridged ring.
[0057] [Item 4]
[0058] The compound or pharmaceutically acceptable salt thereof according to any one of items 1 to 3, wherein
[0059] Ring E represents the following formula (1a-1-1), (1a-2-1), (1a-3-1), (1a-3-2), (1a-3-3) or (1a-3-4):
[0060] [Chemical formula 3]
[0061]
[0062] In the formula,
[0063] X 1 ~X 5 Each independently represents a nitrogen atom or -CR a4 -;
[0064] R a1 ~R a4 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), cyano, C 1-4 Alkoxy (the alkoxy group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 substituted with alkoxy) or a 5- to 10-membered aromatic heterocyclic group, R a2 and R a3 If chemically possible, they can be bonded to the same carbon atom; 1 and X 3 All -CR a4 - In the case of 2 R a4 Together with the carbon atoms to which they are bonded, they can form 1 , X 2 and X 3 The 5-membered ring is condensed to form a 6-membered carbon ring.
[0065] [Item 5]
[0066] The compound or pharmaceutically acceptable salt thereof according to any one of items 1 to 4, wherein
[0067] Ring G represents the following formula (1b-1) or (1b-2):
[0068] [Chemical formula 4]
[0069]
[0070] In the formula,
[0071] W 1 and W 3 Each independently represents a nitrogen atom or -CR b3 -;
[0072] W 2 and W 4 Each independently represents -NR b4 -, oxygen atom or -CR b5 R b6 -;
[0073] R b1 ~R b6 Each independently represents a hydrogen atom, -N(R b7 )R b8 , C 1-6Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms, C 3-6 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkyl substitution, the C 1-4 The alkyl group may be substituted with a halogen atom) or C 1-4 Alkoxy substituted), C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted with 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms which are the same or different), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted), in addition, R b1 and R b2 Can bond to the same carbon atom if chemically possible;
[0074] Here, R b1 and R b2 Available via C 1-6 Alkylene groups are bonded to form any chemically possible bicyclic structure in a fused ring, a spiro ring or a bridged ring;
[0075] R b7 and R b8 Each independently represents a hydrogen atom, C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms, C 1-4 Alkoxy, C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkyl substitution, the C 1-4 The alkyl group may be substituted with a halogen atom) or a 5- to 10-membered aromatic heterocyclic group), a 5- to 10-membered aromatic heterocyclic group (the aromatic heterocyclic group may be substituted with 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted),
[0076] Here, in Rb1 ~R b6 -N(R b7 )R b8 In the case of R b7 and R b8 They may be combined with the nitrogen atom to which they are bonded to form a 3- to 7-membered nitrogen-containing saturated heterocyclic ring.
[0077] [Item 6]
[0078] The compound or pharmaceutically acceptable salt thereof according to any one of items 1 to 5, which is represented by formula (2):
[0079] [Chemical formula 5]
[0080]
[0081] In the formula,
[0082] R 1 and R 2 Each independently represents a hydrogen atom, a halogen atom, a C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substituted) or C 1-4 Alkoxy (the alkoxy group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 3-7 Cycloalkyl substitution);
[0083] -L 1 -Ring G represents -Ring G, -CH2-Ring G (the CH2 may be replaced by one or more identical or different C 1-6 Alkyl substituted), -NR 6 -Ring G, -C(=O)-Ring G, -OC(=O)-Ring G, -SO-Ring G, -SO2-Ring G, -S-Ring G or -O-Ring G;
[0084] R 6 Each independently represents a hydrogen atom or a C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution);
[0085] Ring G represents the following formula (1b-1) or (1b-2):
[0086] [Chemical formula 6]
[0087]
[0088] In the formula,
[0089] W1 and W 3 Each independently represents a nitrogen atom or -CR b3 -;
[0090] W 2 and W 4 Each independently represents -NR b4 -, oxygen atom or -CR b5 R b6 -;
[0091] R b1 ~R b6 Each independently represents a hydrogen atom, -N(R b7 )R b8 , C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms, C 3-6 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkyl substitution, the C 1-4 The alkyl group may be substituted with a halogen atom) or C 1-4 Alkoxy substituted), C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted with 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms which are the same or different), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted), in addition, R b1 and R b2 Can bond to the same carbon atom if chemically possible;
[0092] Here, R b1 and R b2 Available via C 1-6 Alkylene groups are bonded to form any chemically possible bicyclic structure in a fused ring, a spiro ring or a bridged ring;
[0093] R b7 and R b8 Each independently represents a hydrogen atom, C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms, C 1-4 Alkoxy, C3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkyl substitution, the C 1-4 The alkyl group may be substituted with a halogen atom) or a 5- to 10-membered aromatic heterocyclic group), a 5- to 10-membered aromatic heterocyclic group (the aromatic heterocyclic group may be substituted with 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted),
[0094] Here, in R b1 ~R b6 -N(R b7 )R b8 In the case of R b7 and R b8 They can become one with the nitrogen atom to which they are bonded to form a 3-7 membered nitrogen-containing saturated heterocyclic ring;
[0095] A 1 represents an oxygen atom or a sulfur atom;
[0096] j, k, l and m are each independently an integer of 0, 1 or 2;
[0097] The dashed line represents a single bond or a double bond;
[0098] X stands for -CR 7 -, nitrogen atom or carbon atom;
[0099] R 7 represents a hydrogen atom, a hydroxyl group, a halogen atom, a cyano group or a C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution);
[0100] Ring E represents the following formula (1a-1-1), (1a-2-1), (1a-3-1), (1a-3-2), (1a-3-3) or (1a-3-4):
[0101] [Chemical formula 7]
[0102]
[0103] In the formula,
[0104] X 1 ~X 5 Each independently represents a nitrogen atom or -CRa4 -;
[0105] R a1 ~R a4 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), cyano, C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 substituted with an alkoxy group) or a 5- to 10-membered aromatic heterocyclic group, and R a2 and R a3 If chemically possible, they can be bonded to the same carbon atom; 1 and X 3 All -CR a4 - In the case of 2 R a4 Together with the carbon atoms to which they are bonded, they can form 1 , X 2 and X 3 The 5-membered ring is condensed to form a 6-membered carbon ring.
[0106] [Item 7]
[0107] The compound or pharmaceutically acceptable salt thereof according to item 6, wherein
[0108] R 1 and R 2 Each independently represents a hydrogen atom, a halogen atom, a C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution);
[0109] L 1 represents a single bond or an oxygen atom;
[0110] Ring G represents the following formula (1b-1-1), (1b-2-1), (1b-1-2) or (1b-2-2):
[0111] [Chemical formula 8]
[0112]
[0113] In the formula, R b4 , R b7 and R b8 Each independently represents a hydrogen atom or a C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 alkoxy substituted).
[0114] [Item 8]
[0115] The compound or pharmaceutically acceptable salt thereof according to any one of items 1 to 7, which is represented by formula (3):
[0116] [Chemical formula 9]
[0117]
[0118] In the formula,
[0119] L 1 represents a single bond or an oxygen atom;
[0120] Ring G represents the following formula (1b-1-1), (1b-2-1), (1b-1-2) or (1b-2-2):
[0121] [Chemical formula 10]
[0122]
[0123] In the formula, R b4 , R b7 and R b8 Each independently represents a hydrogen atom or a C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted);
[0124] j, k, l and m are each independently an integer of 0, 1 or 2;
[0125] The dashed line represents a single bond or a double bond;
[0126] X stands for -CR 7 -, nitrogen atom or carbon atom;
[0127] R 7 represents a hydrogen atom, a hydroxyl group, a halogen atom, a cyano group or a C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution);
[0128] Ring E represents the following formula (1a-1-1), (1a-2-1), (1a-3-1), (1a-3-2), (1a-3-3) or (1a-3-4):
[0129] [Chemical formula 11]
[0130]
[0131] In the formula,
[0132] X 1 ~X 5 Each independently represents a nitrogen atom or -CR a4 -;
[0133] R a1 ~R a4 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), cyano, C 1-4 Alkoxy (the alkoxy group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 substituted with an alkoxy group) or a 5- to 10-membered aromatic heterocyclic group, and R a2 and R a3 If chemically possible, they can be bonded to the same carbon atom; 1 and X3 All -CR a4 - In the case of 2 R a4 Together with the carbon atoms to which they are bonded, they can form 1 , X 2 and X 3 The 5-membered ring is condensed to form a 6-membered carbon ring.
[0134] [Item 9]
[0135] The compound or pharmaceutically acceptable salt thereof according to any one of items 1 to 8, which is represented by formula (4):
[0136] [Chemical formula 12]
[0137]
[0138] In the formula,
[0139] L 1 represents a single bond or an oxygen atom;
[0140] Ring G represents the following formula (1b-1-1), (1b-2-1), (1b-1-2) or (1b-2-2):
[0141] [Chemical formula 13]
[0142]
[0143] In the formula, R b4 , R b7 and R b8 Each independently represents a hydrogen atom or a C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted);
[0144] The dashed line represents a single bond or a double bond;
[0145] X stands for -CR 7 -, nitrogen atom or carbon atom;
[0146] R 7 Represents a hydrogen atom or C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution);
[0147] Ring E represents the following formula (1a-1-1), (1a-2-1), (1a-3-1), (1a-3-2), (1a-3-3) or (1a-3-4):
[0148] [Chemical formula 14]
[0149]
[0150] In the formula,
[0151] X 1 ~X 5 Each independently represents a nitrogen atom or -CR a4 -;
[0152] R a1 ~R a4 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), cyano, C 1-4 Alkoxy (the alkoxy group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 substituted with alkoxy) or a 5- to 10-membered aromatic heterocyclic group, R a2 and R a3 If chemically possible, they can be bonded to the same carbon atom; 1 and X 3 All -CR a4 - In the case of 2 R a4 Together with the carbon atoms to which they are bonded, they can form 1 , X 2 and X 3 The 5-membered ring is condensed to form a 6-membered carbon ring.
[0153] [Item 10]
[0154] The compound or pharmaceutically acceptable salt thereof according to item 9, wherein
[0155] Ring E represents the above formula (1a-2-1) or (1a-3-1):
[0156] In the formula,
[0157] X 4 ~X 5 Each independently represents a nitrogen atom or -CR a4 -;
[0158] R a1 ~R a4 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted) or C 1-4 Alkoxy group (the alkoxy group may be substituted by 1 or 2 or more halogen atoms which are the same or different).
[0159] [Item 11]
[0160] The compound or pharmaceutically acceptable salt thereof according to item 9, wherein
[0161] Ring E represents the following formula (1a-2-2) or (1a-3-1):
[0162] [Chemical formula 15]
[0163]
[0164] In the formula,
[0165] R a1 ~R a3 Each independently represents a hydrogen atom, a halogen atom, a C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 alkoxy substituted).
[0166] [Item 12]
[0167] The compound or pharmaceutically acceptable salt thereof according to any one of items 1 to 11, which is represented by formula (5):
[0168] [Chemical formula 16]
[0169]
[0170] In the formula,
[0171] L 1 represents a single bond or an oxygen atom;
[0172] Ring G represents the following formula (1b-1-1) or (1b-2-1):
[0173] [Chemical formula 17]
[0174]
[0175] In the formula, R b4 Represents a hydrogen atom or C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted);
[0176] R 7 Represents a hydrogen atom or C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution);
[0177] Ring E represents the following formula (1a-2-2) or (1a-3-1):
[0178] [Chemical formula 18]
[0179]
[0180] In the formula, R a1 ~R a3 Each independently represents a hydrogen atom, a halogen atom, a C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 alkoxy substituted).
[0181] [Item 13]
[0182] The compound or pharmaceutically acceptable salt thereof according to item 12, wherein ring G represents the above formula (1b-1-1), and R b4 is C which may be substituted by 1 or 2 or more halogen atoms which are the same or different 1-4 alkyl.
[0183] [Item 14]
[0184] The compound or pharmaceutically acceptable salt thereof according to item 12, wherein ring G represents the above formula (1b-2-1), and R b4 Represents a hydrogen atom or C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 alkoxy substituted).
[0185] [Item 15]
[0186] The compound or pharmaceutically acceptable salt thereof according to item 12, wherein R 7 A hydrogen atom.
[0187] [Item 16]
[0188] The compound or pharmaceutically acceptable salt thereof according to item 1, which is selected from the following compounds:
[0189] Example 1: (3aR, 5S, 6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0190] Example 2: (3aR, 5S, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-{5-[(1S, 2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0191] Example 3: (1R, 5S, 6R)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-3-azabicyclo[3.1.0]hexane-3-carboxamide;
[0192] Example 4: (1R, 5S, 6S)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-3-azabicyclo[3.1.0]hexane-3-carboxamide;
[0193] Example 6: (3aR, 5R, 6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-methylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0194] Example 7: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-{5-[(1S, 2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-5-methylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0195] Example 8: (3aR, 5R, 6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0196] Example 9: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0197] Example 11: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0198] Example 12: (3aR, 5S, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0199] Example 13: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-methylphenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0200] Example 14: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(2-methylphenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0201] Example 15: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-fluorophenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0202] Example 16: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(3-fluorophenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0203] Example 17: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(2-fluorophenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0204] Example 5-A: (1S,6R,8S)-8-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-3-azabicyclo[4.2.0]octane-3-carboxamide;
[0205] Example 5-B: (1R, 6S, 8R)-8-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-3-azabicyclo[4.2.0]octane-3-carboxamide;
[0206] Example 10-A: (3aS,6aR)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenyl-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0207] Example 10-B: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenyl-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0208] Example 18: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0209] Example 19: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(2-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0210] Example 20: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyridin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0211] Example 21: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0212] Example 22: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(3-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0213] Example 23: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-methylphenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0214] Example 24: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(3-methylphenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0215] Example 25: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyridin-2-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0216] Example 26: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyrimidin-2-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0217] Example 27: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyridin-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0218] Example 28: (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0219] Example 29: (3aR, 6aS)-N-[(1R, 6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-5-phenylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0220] Example 30: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(5-methyl-1,2,4-oxadiazol-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0221] Example 31: (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-5-(5-methyl-1,2,4-oxadiazol-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0222] Example 32: (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-5-(5-methyl-1,2,4-oxadiazol-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0223] Example 33: (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0224] Example 34: (3aR,6aS)-N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-5-phenylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide.
[0225] [Item 17]
[0226] A pharmaceutical composition comprising the compound according to any one of items 1 to 16 or a pharmaceutically acceptable salt thereof.
[0227] [Item 18]
[0228] A pharmaceutical composition comprising a compound according to any one of items 1 to 16 or a pharmaceutically acceptable salt thereof, for use in the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy bodies.
[0229] [Item 19]
[0230] A therapeutic agent for a disease associated with orexin type 2 receptor, comprising the compound according to any one of items 1 to 16 or a pharmaceutically acceptable salt thereof.
[0231] [Item 20]
[0232] A therapeutic agent for the following diseases, comprising a compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 16: narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, hypersomnia associated with Lewy body dementia, hypersomnia syndrome with excessive daytime sleepiness (e.g., Kleine-Levin syndrome, major depression associated with hypersomnia, Lewy body dementia, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, cerebral contusion, cerebral infarction, brain tumor, muscular atrophy, multiple sclerosis, acute disseminated encephalomyelitis, Guillain-Barré syndrome, Barré syndrome, Rasmussen's encephalitis, Wernicke's encephalitis, limbic encephalitis, Hashimoto's encephalitis), lethargy, loss of consciousness, obesity (e.g., malignant mast cells, exogenous obesity, hyperpancreatic obesity, protoplasmic obesity, pituitary obesity, hypoprotoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, pediatric obesity, upper body obesity, dietary obesity, hyposexual obesity, systemic mastocytosis, simple obesity, central obesity), insulin resistance syndrome, Alzheimer's disease, impaired consciousness such as lethargy, side effects or complications caused by anesthesia, sleep disorders, sleep problems, insomnia, intermittent sleep, nocturnal clonic muscle spasms, REM sleep interruption, jet lag , jet lag syndrome, sleep disorders in shift workers, sleep abnormalities, night terrors, depression, major depression, sleepwalking, enuresis, sleep disorders, Alzheimer's crepuscular syndrome, diseases related to circadian rhythm, fibromyalgia, symptoms caused by poor sleep quality, overeating, compulsive eating disorders, obesity-related diseases, hypertension, diabetes, increased plasma insulin concentration and insulin resistance, hyperlipoproteinemia, hyperlipidemia, endometrial cancer, breast cancer, prostate cancer, colon cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease, abnormal heart beat, arrhythmia, myocardial infarction, congestive heart failure, heart failure, coronary heart disease, cardiovascular disease, sudden death, polycystic ovary disease, Craniopharyngioma, Prader-Willi syndrome, Fröhlich syndrome, growth hormone deficiency, normal variant short stature, Turner syndrome, childhood acute lymphoblastic leukemia, syndrome X, reproductive hormone abnormalities, reduced fertility, infertility, male hypogonadism, female male-type hirsutism and other sexual and reproductive dysfunctions, fetal defects related to maternal obesity, gastroesophageal reflux and other gastrointestinal motility diseases related to obesity, obesity hypoventilation syndrome (Pickwick syndrome), respiratory diseases such as dyspnea, systemic inflammation of the vascular system and other inflammation, arteriosclerosis, hypercholesterolemia, hyperuricemia, low back pain, gallbladder disease, gout, kidney cancer, reduce the risk of left ventricular hypertrophy and other secondary consequences of obesity, migraine, headache,Neuropathic pain, Parkinson's disease, psychosis, schizophrenia, facial flushing, night sweats, genital / urinary system diseases, diseases related to sexual function or fertility, depression, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymia, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, anxiety disorder, acute neurological and psychiatric disorders such as brain defects after heart bypass surgery and transplantation, stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic nerve damage, Huntington's disease, amyotrophic lateral sclerosis Coronary sclerosis, multiple sclerosis, eye damage, retinal disease, cognitive impairment, muscle spasms, tremors, epilepsy, disorders related to muscle wasting, delirium, amnesia, cognitive decline associated with age, schizoaffective disorder, paranoia, drug dependence, movement disorders, chronic fatigue syndrome, fatigue, drug-induced parkinsonism, Tourette syndrome, chorea, muscle tremors, tics, restless legs syndrome, dystonia, movement disorders, attention deficit hyperactivity disorder (ADHD), behavioral disorders, urinary incontinence, withdrawal symptoms, trigeminal neuralgia, hearing loss, tinnitus, nerve damage, retinal disease, macular degeneration, vomiting, brain edema, pain, bone pain, joint pain, toothache, cataplexy, or traumatic brain injury.
[0233] [Item 21]
[0234] A therapeutic agent for narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy bodies, comprising a compound according to any one of items 1 to 16 or a pharmaceutically acceptable salt thereof.
[0235] [Item 22]
[0236] A therapeutic agent for narcolepsy, comprising the compound according to any one of Items 1 to 16 or a pharmaceutically acceptable salt thereof.
[0237] [Item 23]
[0238] A therapeutic agent for idiopathic hypersomnia, comprising the compound according to any one of items 1 to 16 or a pharmaceutically acceptable salt thereof.
[0239] [Item 24]
[0240] A method for treating a disease associated with orexin type 2 receptor, comprising administering a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 16 to a patient in need of treatment.
[0241] [Item 25]
[0242] A method for treating narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy bodies, comprising: administering a therapeutically effective amount of a compound described in any one of items 1 to 16 or a pharmaceutically acceptable salt thereof to a patient in need of treatment.
[0243] [Item 26]
[0244] The compound or a pharmaceutically acceptable salt thereof according to any one of Items 1 to 16, for use in the treatment and / or prevention of a disease associated with orexin type 2 receptor.
[0245] [Item 27]
[0246] A compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 16, for use in the treatment and / or prevention of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with Lewy body dementia.
[0247] [Item 28]
[0248] Use of the compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 16 for the manufacture of a therapeutic agent for a disease associated with orexin type 2 receptor.
[0249] [Item 29]
[0250] Use of the compound according to any one of items 1 to 16 or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy bodies.
[0251] [Item 30]
[0252] A drug comprising a compound according to any one of items 1 to 16 or a pharmaceutically acceptable salt thereof in combination with at least one drug selected from the group consisting of therapeutic drugs for diseases classified as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, or therapeutic drugs for Parkinson's disease or dementia with Lewy bodies.
[0253] [Item 31]
[0254] A drug comprising a compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 16, wherein the drug is used in combination with at least one drug selected from drugs for treating diseases classified as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, or drugs for treating Parkinson's disease or dementia with Lewy bodies to treat a disease associated with orexin type 2 receptor. DETAILED DESCRIPTION
[0255] The present invention will be described in further detail below. In this specification, the number of carbon atoms in the definition of a "substituent" may be expressed as, for example, "C 1-6 ” etc. Specifically, “C 1-6 The expression "alkyl" has the same meaning as an alkyl group having 1 to 6 carbon atoms. In addition, in this specification, a substituent that does not specifically indicate the term "may be substituted" or "is substituted" means an "unsubstituted" substituent. For example, "C 1-6 "Alkyl" refers to "unsubstituted C 1-6 alkyl".
[0256] In addition, in the description of substituents in this specification, the term "base" is sometimes omitted. It should be noted that, when defined as "substitutable", the number of substituents when there is a substituent is not particularly limited as long as it can be substituted, and is 1 or more. That is, it means that it can be substituted by a substituent with the number of substitutable carbon atoms or carbon atoms and nitrogen atoms in the group. In addition, unless otherwise indicated, the description of each group also applies to the case where the group is a part of other groups or a substituent.
[0257] Unless otherwise indicated in the present specification, the bonding position of a substituent is any chemically possible position. In the structural formulae in the present specification, wedge-shaped solid and dashed lines represent absolute configurations, and bold solid and dashed lines represent relative configurations.
[0258] Examples of the "halogen" include fluorine, chlorine, bromine, and iodine, and are preferably fluorine or chlorine.
[0259] “C 1-4 "Alkyl" refers to a linear or branched saturated hydrocarbon group having 1 to 4 carbon atoms. 1-6 "Alkyl" refers to a linear or branched saturated hydrocarbon group having 1 to 6 carbon atoms. 1-4 Specific examples of "alkyl" include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. 1-6 Specific examples of "alkyl" include, in addition to the above, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, and their structural isomers. 1-6Alkyl" or "C 1-4 The term "alkyl" refers to methyl, ethyl, propyl and isopropyl, and methyl and isopropyl are more preferred.
[0260] “C 1-6 "Alkylene" refers to a linear or branched divalent saturated hydrocarbon group having 1 to 6 carbon atoms. 1-6 "Alkylene" can preferably be: "C 1-4 "Alkylene" is more preferably: "C 1-3 Alkylene". As "C 1-3 Specific examples of "alkylene" include methylene, ethylene, propylene, trimethylene, etc. As "C 1-4 Specific examples of "alkylene" include, for example, 1-3 In addition to the groups listed as specific examples of "alkylene", butylene, 1,1-dimethylethylene, 1,2-dimethylethylene, 1-methyltrimethylene, 2-methyltrimethylene, etc. can also be listed. 1-6 Specific examples of "alkylene" include, for example, 1-4 In addition to the groups listed as specific examples of "alkylene", there can be mentioned pentylene, 1,1-dimethyltrimethylene, 1,2-dimethyltrimethylene, 1-methylbutylene, 2-methylbutylene, 1-methylpentylene, 2-methylpentylene, 3-methylpentylene, hexylene and the like.
[0261] “C 3-7 "Cycloalkyl" refers to a cyclic non-aromatic hydrocarbon group (saturated hydrocarbon group and partially unsaturated hydrocarbon group) having 3 to 7 carbon atoms. Preferably, "C 3-6 Cycloalkyl". "C 3-7 "Cycloalkyl" also includes bridging groups. As "C 3-7 Specific examples of the "cycloalkyl group" include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, and cycloheptyl.
[0262] The above “C 3-7 "Cycloalkyl" also includes "C 3-7 A bicyclic group formed by condensation of a "cycloalkyl" with a benzene ring or a 5-membered or 6-membered ring containing one or two or more (e.g., 2 to 4) identical or different heteroatoms selected from nitrogen, sulfur or oxygen (e.g., a 5- or 6-membered ring in the "4- to 10-membered saturated heterocycle" described below).
[0263] “C 1-4 "Alkoxy" refers to the above-mentioned "C 1-4 "alkyl" substituted oxy, "C 1-6 "Alkoxy" refers to the above-mentioned "C 1-6 "alkyl" substituted oxygen. As "C 1-4Specific examples of "alkoxy" include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, etc. 1-6 Specific examples of "alkoxy" include, in addition to the above-mentioned "C 1-4 In addition to the groups listed as specific examples of "alkoxy", pentyloxy, hexyloxy, etc. can also be listed. 1-4 Alkoxy" or "C 1-6 The "alkoxy" is preferably methoxy, ethoxy or isopropoxy.
[0264] “C 3-7 "Cycloalkoxy" refers to 3-7 "cycloalkyl" substituted oxy. Preferably "C3-6 cycloalkyloxy". As "C 3-7 Specific examples of the "cycloalkoxy group" include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, etc. Preferably, it is cyclohexyloxy.
[0265] “C 6-10 "Aromatic carbocyclic group" refers to an aromatic hydrocarbon group having 6 to 10 carbon atoms, also known as "C 6-10 Aryl. As "C 6-10 Specific examples of the "aromatic carbocyclic group" include phenyl, 1-naphthyl, 2-naphthyl, etc. More preferably, it is phenyl.
[0266] The above “C 6-10 The "aromatic carbocyclic group" also includes a group formed by the condensation of a "phenyl group" with a 5- or 6-membered ring containing one or two or more (e.g., 2 to 4) identical or different heteroatoms selected from nitrogen, sulfur or oxygen (e.g., the "5- or 6-membered monocyclic aromatic heterocyclic group" described below, the 5- or 6-membered ring in the "4- to 10-membered saturated heterocycle" described below) or a 5- to 7-membered cycloalkyl ring (e.g., cyclopentane, cyclohexane or cycloheptane).
[0267] The "5- to 10-membered aromatic heterocyclic group" refers to a monocyclic or polycyclic 5- to 10-membered aromatic heterocyclic group containing, in addition to carbon atoms constituting the ring, one or two or more (e.g., 2 to 4) the same or different heteroatoms selected from nitrogen, sulfur or oxygen. Preferably, it is a "5- or 6-membered monocyclic aromatic heterocyclic group". The "5- or 6-membered monocyclic aromatic heterocyclic group" refers to a monocyclic 5- or 6-membered aromatic group in the "5- to 10-membered aromatic heterocyclic group".
[0268] Specific examples of the polycyclic aromatic heterocyclic group in the above-mentioned “5- to 10-membered aromatic heterocyclic group” include: a group formed by condensing two identical or different monocyclic aromatic heterocyclic rings, or a group formed by condensing a monocyclic aromatic heterocyclic ring with an aromatic ring (e.g., benzene, etc.) or a non-aromatic ring (e.g., cyclohexane, etc.).
[0269] Specific examples of the "5- to 10-membered aromatic heterocyclic group" include pyrazolyl, imidazolyl, benzofuranyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, etc. In another embodiment, preferably, benzofuranyl (bonding position is on the heteroaryl (furan) ring), pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, etc. are included.
[0270] “C 3-6 "Saturated carbocycle" refers to a monocyclic saturated or partially unsaturated hydrocarbon ring having 3 to 6 carbon atoms. 3-6 Specific examples of the "saturated carbon ring" include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cyclohexadiene, and the like. Preferably, cyclopropane or cyclobutane is mentioned.
[0271] "4- to 10-membered saturated heterocycle" refers to a monocyclic or bicyclic saturated heterocycle composed of 4 to 10 atoms, which contains, in addition to carbon atoms constituting the ring, one or more (e.g., 2 to 4, preferably 2 to 3, more preferably 2) heteroatoms selected from oxygen atoms, nitrogen atoms, and sulfur atoms, which may be the same or different, and includes a ring having a partially unsaturated bond, a ring having a partially bridged structure, and a partially spirocyclic ring. Preferably, it is a 5- or 6-membered saturated heterocycle. Bicyclic saturated heterocycles also include rings formed by condensation of a monocyclic saturated heterocycle with benzene or a monocyclic 5- to 6-membered aromatic heterocycle. In addition, in order to constitute the saturated heterocycle, one or two carbonyl groups, thiocarbonyl groups, sulfinyl groups, or sulfonyl groups may be included. For example, cyclic groups such as lactams, thiolactams, lactones, thiolactones, cyclic imides, cyclic carbamates, and cyclic thiocarbamates are also included in the saturated heterocycle. Among them, the oxygen atom of the carbonyl, sulfinyl and sulfonyl groups and the sulfur atom of the thiocarbonyl group are not included in the number of 4 to 10 members (ring size) and the number of heteroatoms constituting the ring. As the "4 to 10-membered saturated heterocyclic ring", preferably, a monocyclic or bicyclic "4 to 8-membered saturated heterocyclic ring" is mentioned, more preferably, a monocyclic "4 to 6-membered saturated heterocyclic ring" is mentioned, and further preferably, a monocyclic "5 or 6-membered saturated heterocyclic ring" is mentioned. Specific examples of the "4 to 10-membered saturated heterocyclic ring" include piperazine, oxetane, azetidine, pyrrolidine, pyrazolidine, imidazolidine, piperidine, morpholine, homopiperidine, thiomorpholine, dioxothiomorpholine, hexamethyleneimine, oxazolidine, thiazolidine, oxoimidazolidine, dioxoimidazolidine, oxazolidine, dioxoxazolidine, dioxothiazolidine, tetrahydrofuran, tetrahydropyran, tetrahydropyridine, and the like. Preferred are pyrrolidine, piperidine, piperazine and morpholine. Specific examples of bicyclic saturated heterocycles include indoline, isoindoline, dihydropurine, dihydrothiazolopyrimidine, dihydrobenzodioxane, dihydroindazole, dihydropyrrolopyridine, tetrahydroquinoline, decahydroquinoline, tetrahydroisoquinoline, decahydroisoquinoline, tetrahydronaphthyridine, tetrahydropyridoazepine, wait.
[0272] The "4- to 6-membered saturated heterocyclic group" refers to a substituent in which the "4- to 6-membered saturated heterocyclic ring" in the above-mentioned "4- to 10-membered saturated heterocyclic ring" is a monovalent group. Preferred examples include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and the like.
[0273] The compounds of the present invention also include various hydrates, solvates and polymorphs.
[0274] In addition, the compounds of the present invention may be substituted with isotopes (e.g., D, 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 35 S. 18 F. 125 I, etc.), these compounds are also included in the compounds of the present invention.
[0275] The compounds of the present invention also include all tautomers, all existing stereoisomers, and mixtures thereof.
[0276] For example, the optically active form of the compound of the present invention can be produced by using an optically active starting material or by optically resolving the racemate of the final product. Examples of optical resolution methods include physical separation methods using optically active columns and chemical separation methods such as fractional crystallization.
[0277] In the present invention, "pharmaceutically acceptable salt" refers to an acid addition salt and a base addition salt that are permitted for pharmaceutical use. "Pharmaceutically acceptable salt" is not limited to these, and examples thereof include acetate, propionate, butyrate, formate, trifluoroacetate, maleate, fumarate, tartrate, citrate, stearate, succinate, ethylsuccinate, malonate, lactobionate, gluconate, glucoheptonate, benzoate, methanesulfonate, benzenesulfonic acid, p-toluenesulfonate (tosylate), lauryl sulfate, malate, ascorbate, mandelate, sugar Acid addition salts such as lithinate, xinafoate, pamoate, cinnamate, adipate, cysteine, N-acetylcysteine, hydrochloride, hydrobromide, phosphate, sulfate, hydroiodide, nicotinate, oxalate, picrate, thiocyanate, undecanoate, acrylic acid polymer salt, carboxyvinyl polymer; inorganic base addition salts such as lithium salt, sodium salt, potassium salt, calcium salt; organic base addition salts such as morpholine, piperidine; addition salts with amino acids such as aspartic acid and glutamic acid, etc.
[0278] The compound of the present invention can be administered by oral administration or parenteral administration directly or using appropriate dosage forms to prepare preparations, medicines or pharmaceutical compositions. As specific examples of these dosage forms, they are not limited to these, and for example, tablets, capsules, powders, granules, liquid preparations, suspensions, injections, patches, dressings, etc. can be listed. In addition, these preparations can be manufactured according to known methods using conventional additives used as pharmaceutical additives.
[0279] As these additives, excipients, disintegrants, binders, fluidizers, lubricants, coating agents, solubilizers, solubilizers, thickeners, dispersants, stabilizers, sweeteners, flavors, etc. can be used according to the purpose. Specific examples of these additives are not limited to these, and examples thereof include lactose, mannitol, crystalline cellulose, low-substituted hydroxypropyl cellulose, corn starch, partially alpha-starch, carmellose calcium, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, propylene glycol, titanium dioxide, talc, etc.
[0280] The dosage of the compound of the present invention is appropriately selected according to the animal to be administered, the route of administration, the disease, the age, weight and symptoms of the patient. For example, in the case of oral administration, for adults, the lower limit is 0.01 mg per day and the upper limit is 10000 mg, and the amount can be administered once a day or in divided doses.
[0281] The compound of the present invention is a compound with agonist activity to orexin type 2 receptor. Therefore, it can be a useful therapeutic or preventive drug for diseases related to orexin type 2 receptor. As a specific example of these diseases, narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, hypersomnia associated with Lewy body dementia, hypersomnia syndrome with excessive daytime sleepiness (for example, Klein-Levin syndrome, severe depression associated with hypersomnia, Lewy body dementia, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome, C-type Niemann-Pick disease, cerebral contusion, cerebral infarction, brain tumor, muscular atrophy, multiple sclerosis, acute disseminated encephalomyelitis, Guillain-Barre syndrome, Rasmussen's Encephalitis, Wernicke's encephalitis, limbic encephalitis, Hashimoto's encephalitis), lethargy, loss of consciousness, obesity (e.g., malignant mast cells, exogenous obesity, hyperpancreatic obesity, protoplasmic obesity, pituitary obesity, hypoprotoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, pediatric obesity, upper body obesity, dietary obesity, hyposexual obesity, systemic mastocytosis, simple obesity, central obesity), insulin resistance syndrome, Alzheimer's disease, impaired consciousness such as lethargy, side effects or complications caused by anesthesia, sleep disorders, sleep problems, insomnia, intermittent sleep, nocturnal clonic muscle spasms, REM sleep interruption , jet lag, jet lag syndrome, sleep disorders in shift workers, parasomnias, night terrors, depression, major depression, sleepwalking, enuresis, sleep disorders, Alzheimer's crepuscular syndrome, diseases related to circadian rhythm, fibromyalgia, symptoms caused by poor sleep quality, overeating, compulsive eating disorders, obesity-related diseases, hypertension, diabetes, increased plasma insulin concentration and insulin resistance, hyperlipoproteinemia, hyperlipidemia, endometrial cancer, breast cancer, prostate cancer, colon cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, cholelithiasis, heart disease, abnormal heart beat, arrhythmia, myocardial infarction, congestive heart failure, heart failure, Coronary heart disease, cardiovascular disease, sudden death, polycystic ovary disease, craniopharyngioma, Prader-Willi syndrome, Fröhlich syndrome, growth hormone deficiency, normal variant short stature, Turner syndrome, childhood acute lymphoblastic leukemia, syndrome X, reproductive hormone abnormalities, reduced fertility, infertility, male hypogonadism, female male-type hirsutism and other sexual and reproductive dysfunctions, fetal defects related to maternal obesity, gastroesophageal reflux and other gastrointestinal motility diseases related to obesity, obesity hypoventilation syndrome (Pickwick syndrome), respiratory diseases such as dyspnea, systemic inflammation of the vascular system and other inflammations, arteriosclerosis, hypercholesterolemia, hyperuricemia, low back pain, gallbladder disease,gout, kidney cancer, reduced risk of left ventricular hypertrophy and other secondary consequences of obesity, migraine, headache, neuropathic pain, Parkinson's disease, psychosis, schizophrenia, facial flushing, night sweats, genital / urinary system diseases, diseases related to sexual function or fertility, depression, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymia, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, anxiety disorder, acute neurological and psychiatric disorders such as brain defects after heart bypass surgery and transplantation, stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemia Nerve damage, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, eye damage, retinal disease, cognitive impairment, muscle spasms, tremors, epilepsy, disorders related to muscle wasting, delirium, amnesia, cognitive decline associated with age, schizoaffective disorder, paranoia, drug dependence, movement disorders, chronic fatigue syndrome, fatigue, drug-induced parkinsonism, Tourette syndrome, chorea, muscle tremors, tics, restless legs syndrome, dystonia, movement disorders, attention deficit hyperactivity disorder (ADHD), behavioral disorders, urinary incontinence, withdrawal symptoms, trigeminal neuralgia, hearing loss, tinnitus, nerve damage, retinal disease, macular degeneration, vomiting, brain edema, pain, bone pain, joint pain, toothache, cataplexy, or traumatic brain injury. Preferably, the drug is narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, and hypersomnia associated with dementia with Lewy bodies.
[0282] The compound of the present invention is a compound having agonist activity on orexin type 2 receptor, and therefore can be a useful therapeutic drug or preventive agent for diseases associated with orexin type 2 receptor. The compound of the present invention is particularly effective for the sleep-wake disorder group. Specific examples of such diseases include insomnia disorder, hypersomnia disorder, narcolepsy, narcolepsy without cataplexy but with orexin (hypothalamocretin) deficiency, narcolepsy with cataplexy but without orexin (hypothalamocretin) deficiency, autosomal dominant cerebellar ataxia with deafness and narcolepsy, autosomal dominant narcolepsy with obesity and type 2 diabetes, narcolepsy secondary to other medical diseases, breathing-related sleep disorder group, circadian rhythm sleep-wake disorder group, syndrome associated with sleep, weak foot paresthesia (restless legs syndrome), substance / drug-induced sleep disorder, other specific insomnia disorder, unspecified insomnia disorder, other specific hypersomnia disorder, unspecified hypersomnia disorder, other specific sleep-wake disorder, and unspecified sleep-wake disorder.
[0283] In the present invention, "prevention" refers to the act of administering the compound of the present invention to a healthy person who has not developed a disease, for example, for the purpose of preventing the onset of a disease. "Treatment" refers to the act of administering the compound of the present invention to a person (patient) diagnosed by a doctor as having developed a disease, for example, for the purpose of alleviating the disease or symptoms, or restoring to the state before the onset of the disease. In addition, even if the purpose of administration is to prevent the deterioration of a disease or symptom, as long as the person being administered is a patient, it is also a therapeutic act.
[0284] The compound of the present invention can be used in combination with a therapeutic drug for diseases such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, or a therapeutic drug for Parkinson's disease or dementia with Lewy bodies as a concomitant drug. As therapeutic drugs for diseases such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, for example, amphetamine, methylphenidate, modafinil, armodafinil, sodium oxybate, tirolisen, soanfitol, etc. Examples of therapeutic drugs for Parkinson's disease or dementia with Lewy bodies include levodopa, carbidopa, entacapone, MAOB inhibitors (e.g., zonisamide, selegiline, rasagiline, safinamide, etc.), dopamine receptor agonists (e.g., bromocriptine, pergolide, talipexol, cabergoline, pramipexole, ropinirole, rotigotine, apomorphine, etc.), amantadine, droxidopa, istraphylline, anticholinergics (e.g., trihexyphenidyl, biperiden, etc.), and the like.
[0285] There is no limitation on the administration period of the compound of the present invention and the concomitant drug, and these can be administered to the administration subject at the same time, or the administration can be performed at intervals. In addition, a mixture of the compound of the present invention and the concomitant drug can be prepared. The dosage of the concomitant drug can be appropriately selected based on the dosage (dosage) used clinically. In addition, the blending ratio of the compound of the present invention and the concomitant drug can be appropriately selected according to the administration subject, administration route, target disease, symptoms, combination, etc.
[0286] Hereinafter, the method for producing the compound represented by formula (1) in the present invention will be described by way of example, but the present invention is of course not limited thereto.
[0287] Manufacturing method
[0288] The compound of the present invention can be synthesized by the production method shown below and a method combining known synthesis methods.
[0289] The compounds in the reaction formula also include the case where they form respective salts, and examples of such salts include the same salts as the above-mentioned "pharmaceutically acceptable salts". It should be noted that these reactions are merely illustrative, and based on the knowledge of those familiar with organic synthetic chemists, the compounds of the present invention may also be appropriately prepared by other methods.
[0290] In each of the production methods described below, even when the use of a protecting group is not specifically indicated, if there is a functional group that needs to be protected, the functional group may be protected as necessary and deprotected after completion of the reaction or after a series of reactions to obtain the target product.
[0291] As the protecting group, for example, a common protecting group described in the literature (TW Greene and PGM Wuts, "Protective Groups in Organic Synthesis", 3rd Ed., John Wiley and Sons, inc., New York (1999)) etc. can be used. More specifically, as the protecting group of the amino group, for example, tert-butoxycarbonyl, benzyloxycarbonyl, p-toluenesulfonyl, o-nitrobenzenesulfonyl, tetrahydropyranyl and the like can be mentioned. In addition, as the protection of the hydroxyl group, for example, trialkylsilyl, acetyl, benzyl, tetrahydropyranyl, methoxymethyl and the like can be mentioned. As the protecting group of the aldehyde group, for example, dialkyl acetal, cyclic alkyl acetal and the like can be mentioned. As the protecting group of the carboxyl group, for example, tert-butyl ester, orthoester, amide and the like can be mentioned.
[0292] The introduction and removal of the protecting group can be carried out by a method commonly used in organic synthetic chemistry (for example, the method described in TW Greene and P. GM Wuts, "Protective Groups in Organic Synthesis", 3rd Ed., John Wiley and Sons, inc., New York (1999)) or a method based thereon.
[0293] Manufacturing method 1:
[0294] The compound represented by formula (1) or a pharmaceutically acceptable salt thereof can be produced, for example, by the following production method.
[0295] [Chemical formula 19]
[0296]
[0297] In the formula, R 1 , R 2 , L 1 ,j,k,l,m,n,ring G,A 1, the dotted part, X and ring E have the same meanings as in item 1.
[0298] Step (1-1):
[0299] Compound (s-1-1) can be prepared by reacting compound (s-1-2) and compound (s-1-3) in a suitable inert solvent under the conditions for forming a urea bond that are usually used. The conditions for this reaction include, for example, conditions using triphosgene, 4-nitrophenyl chloroformate, 1,1'-carbonyldiimidazole or thiophosgene. A base is used in this reaction, and examples of the base used include triethylamine and diisopropylethylamine. Examples of inert solvents include halogenated carbons such as chloroform and dichloromethane; ether solvents such as diethyl ether, THF, and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; and ester solvents such as ethyl acetate and methyl acetate. The reaction time is usually about 1 to 24 hours, and the reaction temperature is -20°C to the boiling point of the solvent.
[0300] In step (1-1), the isocyanate or the like as an intermediate may be isolated and then further converted.
[0301] Manufacturing method 2:
[0302] Among the compounds represented by the formula (s-1-2), the compound represented by the formula (s-2-1) can be produced, for example, by the following production method.
[0303] [Chemical formula 20]
[0304]
[0305] In the formula, R 7 , R a1 , Q 2 , j, k, l and m have the same meanings as in item 1. In addition, P 1 represents an appropriate protecting group, and has the same meaning unless otherwise specified below.
[0306] Step (2-1):
[0307] Compound (s-2-4) can be prepared by reacting compound (s-2-2) and compound (s-2-3) in a suitable inert solvent under commonly used addition reaction conditions. Examples of the inert solvent include: halogenated carbons such as chloroform and dichloromethane; ether solvents such as diethyl ether, THF, and 1,4-dihexane; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; alcohol solvents such as methanol or ethanol; and water. The reaction time is generally about 1 to 24 hours, and the reaction temperature is -20°C to the boiling point of the solvent.
[0308] Step (2-2):
[0309] Compound (s-2-6) can be prepared by reacting compound (s-2-4) and compound (s-2-5) in a suitable inert solvent under the conditions of a condensation reaction generally used. The conditions of this reaction can be, for example, conditions using HATU, DCC or CDI. In this reaction, a base is used depending on the situation. Examples of the base used include triethylamine and diisopropylethylamine. Examples of solvents include halogenated carbons such as chloroform and dichloromethane; ether solvents such as diethyl ether, THF, and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; and ester solvents such as ethyl acetate and methyl acetate. The reaction time is generally about 1 to 24 hours, and the reaction temperature is -20°C to the boiling point of the solvent.
[0310] Steps (2-3):
[0311] Compound (s-2-7) can be prepared by reacting compound (s-2-6) in a suitable inert solvent under the dehydration reaction conditions commonly used. A base such as triethylamine or DBU can be used in this reaction depending on the situation. Examples of inert solvents include: halogenated carbons such as chloroform and dichloromethane; ether solvents such as diethyl ether, THF, and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; and ester solvents such as ethyl acetate and methyl acetate. The reaction time is generally about 1 to 24 hours, and the reaction temperature is -20°C to the boiling point of the solvent.
[0312] Steps (2-4):
[0313] Compound (s-2-1) was prepared by a known method (e.g., Protective Groups in Organic Synthesis 3 rd The compound (s-2-7) can be prepared by deprotecting the protecting group in the same manner as described in 1996's (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, RC Larock et al., VCH publisher Inc., 1989).
[0314] Manufacturing method 3:
[0315] Among the compounds represented by the formula (s-1-2), the compound represented by the formula (s-3-1) can be produced, for example, by the following production method.
[0316] [Chemical formula 21]
[0317]
[0318] In the formula, R a2 , R a3, X 6 , X 7 , X 8 , j, k, l and m have the same meanings as in item 1. In addition, M represents a metal such as lithium or magnesium halide. Furthermore, Z represents boric acid, boric acid ester, BF3K, BF3Na, trialkyltin, zinc halide or hydrogen atom, and Y represents halogen.
[0319] Compound (s-3-1) can be synthesized from compound (s-3-2) through steps (3-1) to (3-3). Step (3-1):
[0320] Compound (s-3-4) can be prepared by reacting compound (s-3-2) and compound (s-3-3) in a suitable inert solvent under the conditions of addition reaction of ketones generally used without additives or in the presence of a Lewis acid. Examples of the Lewis acid used in this reaction include zinc (II) chloride, scandium (III) trifluoromethanesulfonate, copper (I) chloride, boron trifluoride, boric acid, boric acid esters, and the like. Examples of the inert solvent include halogenated carbons such as chloroform and dichloromethane; ether solvents such as diethyl ether, THF, and 1,4-dioxane; and aromatic hydrocarbon solvents such as benzene, toluene, and xylene. The reaction time is generally about 1 to 24 hours, and the reaction temperature is -78°C to the boiling point of the solvent.
[0321] Step (3-2):
[0322] Compound (s-3-5) can be prepared by reacting compound (s-3-4) in a suitable inert solvent under the conditions of a dehydration reaction generally used. The conditions of the dehydration reaction refer to the conditions of using a dehydrating agent such as an acid or Burgess reagent or the conditions of a Mitsunobu reaction or the like, or the conditions of a leaving group after converting a hydroxyl group (after mesylation or toluenesulfonylation, or halogen substitution, etc.) into a leaving group, and then using a base or the like to carry out a leaving reaction. As the acid used in this reaction, for example, proton acids such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid, or Lewis acids such as zinc chloride (II), scandium trifluoromethanesulfonate (III), copper chloride (I), boron trifluoride, boric acid, and boric esters can be listed. In addition, as the base used in this reaction, for example, there can be listed: organic bases such as triethylamine, diisopropylethylamine or DBU, or inorganic bases such as sodium bicarbonate, sodium carbonate, potassium carbonate, etc.; metal alkoxides such as potassium tert-butoxide; organic metal reagents such as n-butyl lithium or isopropyl magnesium chloride; metal amide reagents such as LDA or LHMDS, etc. As the inert solvent, for example, there can be listed: halogenated carbons such as chloroform and dichloromethane; ether solvents such as diethyl ether, THF, 1,4-dioxane, etc.; aromatic hydrocarbon solvents such as benzene, toluene, xylene, etc.; ester solvents such as ethyl acetate and methyl acetate. The reaction time is usually about 1 hour to 24 hours, and the reaction temperature is -78°C to the boiling point of the solvent.
[0323] Step (3-3):
[0324] Compound (s-3-1) can be produced using compound (s-3-5) under the same conditions as in step (2-4).
[0325] Compound (s-3-5) can also be synthesized from compound (s-3-2) via steps (3-4) and (3-5).
[0326] Steps (3-4):
[0327] Compound (s-3-6) can be prepared by reacting a commonly used triflate (triflating) agent with compound (s-3-2) in a suitable inert solvent, in the absence of additives, or in the presence of an acid or a base (or in the presence of both an acid and a base). Examples of the triflate agent used in this reaction include trifluoromethanesulfonic anhydride or N-phenylbis(trifluoromethanesulfonyl imide). Examples of the acid used in this reaction include Lewis acids such as zinc (II) chloride, scandium (III) trifluoromethanesulfonate, copper (I) chloride, boron trifluoride, boric acid, and boric acid esters. In addition, examples of the base used in this reaction include organic bases such as triethylamine, diisopropylethylamine, or DBU, or inorganic bases such as sodium bicarbonate, sodium carbonate, and potassium carbonate, metal alkoxides such as potassium tert-butoxide, organic metal reagents such as n-butyllithium or isopropylmagnesium chloride, and metal amide reagents such as LDA or LHMDS. Examples of the inert solvent include halogenated carbons such as chloroform and dichloromethane; ether solvents such as diethyl ether, THF, and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; and ester solvents such as ethyl acetate and methyl acetate. The reaction time is usually about 1 to 24 hours, and the reaction temperature is from -78°C to the boiling point of the solvent.
[0328] Steps (3-5):
[0329] Compound (s-3-5) can be prepared by reacting compound (s-3-6) in a suitable inert solvent in the presence of a palladium catalyst and a phosphine ligand, and in the presence of a base if necessary, with a compound (s-3-7) in which Z is represented by boric acid, boric acid ester, BF3K, BF3Na, trialkyltin or zinc halide. Compound (s-3-7) can be used as a commercially available compound or a compound synthesized by a known method or a method based thereon. As a palladium catalyst, for example, tetrakis(triphenylphosphine)palladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0), bis(tri-tert-butylphosphine)palladium(0), palladium acetate(0), [1,1-bis(diphenylphosphino)ferrocene]palladium(II)dichloride, bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II), etc.
[0330] Examples of the phosphine ligand include o-tolylphosphine, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (S-Phos), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-Phos), 1,1'-bis(diphenylphosphino)ferrocene (DPPF), 1,2-bis(diphenylphosphino)ethane (DPPE), 1,3-bis(diphenylphosphino)propane (DPPP), 1,4-bis(diphenylphosphino)butane (DPPB), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XANT-Phos), and bis(2-(diphenylphosphino)phenyl)ether (DPE-Phos). Examples of the base include sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydroxide, potassium hydroxide, etc. Examples of the inert solvent include 1,4-dioxane, THF, 1,2-dimethoxyethane, acetonitrile, water, and mixed solvents thereof. The reaction time is generally about 1 to 24 hours, and the reaction temperature is -20°C to the boiling point of the solvent.
[0331] Compound (s-3-5) can also be synthesized from compound (s-3-2) via steps (3-6) and (3-7).
[0332] Steps (3-6):
[0333] Compound (s-3-8) can be prepared in a suitable inert solvent under the conditions of a vinyl halide formation reaction generally used. The conditions of the vinyl halide formation reaction used in this reaction include, for example, the conditions of reacting hydrazine and then tetramethylguanidine and iodine, or the conditions of reacting phosphorous acid and bromine in the presence of triethylamine, or the conditions of reacting a chlorination reagent such as phosphorus pentachloride or phosphorus trichloride, etc. As an inert solvent, for example, halogenated carbons such as chloroform and dichloromethane; ether solvents such as diethyl ether, THF, and 1,4-dihydrogen ether; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; ester solvents such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -78°C to the boiling point of the solvent.
[0334] Steps (3-7):
[0335] Compound (s-3-5) can be produced using compound (s-3-8) under the same conditions as in step (3-5).
[0336] Manufacturing method 4:
[0337] Among the compounds represented by the formula (s-1-2), the compound represented by the formula (s-4-1) can be produced, for example, by the following production method.
[0338] [Chemical formula 22]
[0339]
[0340] In the formula, R a2 , R a3 , X 6 , X 7 , X 8 , j, k, l and m have the same meanings as in item 1.
[0341] Compound (s-4-1) can be synthesized from compound (s-3-5) via step (4-1) and step (4-2), or from compound (s-3-1) via step (4-3).
[0342] Step (4-1):
[0343] Compound (s-4-2) can be prepared by reacting compound (s-3-5) in a suitable inert solvent, or if necessary, in a hydrogen atmosphere, under additive-free conditions, or in the presence of an acid, under generally used double bond reduction reaction conditions. The conditions of this reaction include, for example, conditions using palladium carbon or palladium (II) hydroxide, Raney nickel, or conditions using a hydride reducing agent such as triethylsilane. Examples of the acid used in this reaction include protonic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid. Examples of inert solvents include halogenated carbons such as chloroform and dichloromethane; ether solvents such as diethyl ether, THF, and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; ester solvents such as ethyl acetate and methyl acetate; and alcohol solvents such as methanol or ethanol. The reaction time is generally about 1 to 24 hours, and the reaction temperature is -20°C to the boiling point of the solvent.
[0344] Step (4-2):
[0345] Compound (s-4-1) can be produced using compound (s-4-2) under the same conditions as in step (2-4).
[0346] Step (4-3):
[0347] Compound (s-4-1) can be produced using compound (s-3-1) under the same conditions as in step (4-1).
[0348] Manufacturing method 5:
[0349] Among the compounds represented by the formula (s-1-2), the compound represented by the formula (s-5-1) can be produced, for example, by the following production method.
[0350] [Chemical formula 23]
[0351]
[0352] In the formula, R a2 , R a3 , X 6 , X 7 , X 8 , j, k, l and m have the same meanings as in item 1. In addition, Y represents a halogen.
[0353] Compound (s-5-1) can be synthesized from compound (s-5-2) via steps (5-1) and (5-2). Step (5-1):
[0354] Compound (s-5-4) can be prepared by reacting compound (s-5-2) in a suitable inert solvent in the presence of a palladium catalyst, a phosphine ligand and a base with compound (s-5-3). Compound (s-5-3) can be used as a commercially available compound or a compound synthesized by a known method or a method based thereon. As a palladium catalyst, for example, tetrakis(triphenylphosphine)palladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0), bis(tri-tert-butylphosphine)palladium(0), palladium acetate(0), [1,1-bis(diphenylphosphino)ferrocene]palladium(II)dichloride, bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II), etc.
[0355] Examples of the phosphine ligand include o-tolylphosphine, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (S-Phos), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-Phos), 1,1'-bis(diphenylphosphino)ferrocene (DPPF), 1,2-bis(diphenylphosphino)ethane (DPPE), 1,3-bis(diphenylphosphino)propane (DPPP), 1,4-bis(diphenylphosphino)butane (DPPB), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XANT-Phos), and bis(2-(diphenylphosphino)phenyl)ether (DPE-Phos). Examples of the base include sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydroxide, potassium hydroxide, etc. Examples of the inert solvent include 1,4-dioxane, THF, 1,2-dimethoxyethane, acetonitrile, water, and mixed solvents thereof. The reaction time is generally about 1 to 24 hours, and the reaction temperature is -20°C to the boiling point of the solvent.
[0356] In step (5-1), when compound (s-5-3) is a compound that undergoes an aromatic nucleophilic substitution reaction, compound (s-5-4) can also be synthesized by reacting compound (s-5-2) with compound (s-5-3) under the reaction conditions.
[0357] Step (5-2):
[0358] Compound (s-5-1) can be produced using compound (s-5-4) under the same conditions as in step (2-4).
[0359] Example
[0360] The present invention will be described in more detail below by reference examples, examples and test examples, but the present invention is not limited thereto. It should be noted that the names of the compounds shown in the following reference examples and examples are not necessarily based on the IUPAC nomenclature.
[0361] In this specification, the following abbreviations may be used.
[0362] n-: positive;
[0363] tert-: uncle;
[0364] p-: yes;
[0365] CDCl3: deuterated chloroform;
[0366] Rt: retention time;
[0367] min: minute;
[0368] HATU: O-(7-aza-1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate;
[0369] DCC: N,N'-dicyclohexylcarbodiimide;
[0370] CDI: carbonyldiimidazole;
[0371] THF: tetrahydrofuran;
[0372] TFA: trifluoroacetic acid;
[0373] DMSO: dimethyl sulfoxide;
[0374] Boc: tert-butoxycarbonyl;
[0375] DBU: diazabicycloundecene;
[0376] LDA: lithium diisopropylamide;
[0377] LHMDS: lithium bis(trimethylsilyl)amide.
[0378] Column chromatography and amino chromatography in Reference Examples and Examples used silica gel columns and amino columns manufactured by Yamazen Co., Ltd. When purification was performed using TLC, Silica gel 60 F254 (Merck) was used for TLC (silica gel plate), and TLC plate NH (Fuji Silysia) was used for TLC (NH silica gel plate).
[0379] The following reaction apparatuses were used in Reference Examples and Examples. The physicochemical data described in Reference Examples and Examples were obtained by the following instruments.
[0380] Microwave reaction apparatus: Biotage AB Initiator;
[0381] 1 H-NMR: JEOLJNM-AL400; JEOLJNM-ECS400; BruckerAVANCE 400Spectrometer.
[0382] As symbols used in NMR, s means singlet, d means doublet, dd means double of doublet, ddd means double of doublet of doublet, dddd means double of double of doublet of doublet, t means triplet, td means double of triplet, q means quartet, m means multiplet, br means broad singlet or multiplet, and J means bond constant.
[0383] The LC / MS data of each compound in Examples and Reference Examples were acquired by any of the following instruments.
[0384] Method A
[0385] Detection instrument: ACQUITY (registered trademark) SQ detector (Waters Corporation);
[0386] HPLC: ACQUITY UPLC (registered trademark) SYSTEM;
[0387] Column: Waters ACQUITY UPLC (registered trademark) BEH C18 (1.7 μm, 2.1 mm×30 mm);
[0388] Method B
[0389] Detection instrument: Shimadzu LCMS-2020;
[0390] Column: PhenomenexKinetex (C18, 1.7μm, 2.1mm×50mm).
[0391] High performance liquid chromatography mass spectrometry; the measurement conditions of LC / MS are as follows, and the observed mass spectrum values [MS (m / z)] are expressed as [M+H] + The retention time is expressed as Rt (min).
[0392] Method A
[0393] Solvent: Solution A: 0.06% formic acid / H2O, Solution B: 0.06% formic acid / acetonitrile;
[0394] Gradient conditions: 0.0-1.3 min (linear gradient from B 2% to B 96%);
[0395] Flow rate: 0.8 mL / min; UV detection: 220 nm and 254 nm; Temperature: 40 °C;
[0396] In the following, LC-MS data are obtained by method A unless otherwise specified.
[0397] Method B
[0398] Solvent: Solution A: 0.05% TFA / H2O, Solution B: acetonitrile;
[0399] Gradient conditions: 0.0-1.7 min (linear gradient from 10% B to 99% B), 1.7-1.9 min (99% B), 1.9-3.0 min (10% B);
[0400] Flow rate: 0.5 mL / min; detection UV: 254 nm; temperature: 40°C.
[0401] Embodiment 1:
[0402] (3aR,5S,6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide
[0403] [Chemical formula 24]
[0404]
[0405] At -20°C, add 1.4 mL chloroform solution of 100 mg of compound 1 (raw material A) known from the literature and 0.4 mL chloroform solution of 160 μL triethylamine, and stir at this temperature for 40 minutes. Add the reaction mixture to 92 mg of the compound of reference example 4 (raw material B) and 0.5 mL chloroform solution of 107 μL triethylamine at 0°C, and stir at room temperature for 1 hour. Add water to the reaction mixture and extract with chloroform. Dry the organic layer with anhydrous sodium sulfate, concentrate under reduced pressure, and purify the residue with silica gel column chromatography (eluent: chloroform / methanol) to obtain 168 mg of the title compound 2.
[0406] 1 H-NMR(CDCl3)δ:1.01(6H,d,J=6.0Hz),1.17-1.23(4H,m),1.23-1.47(2H,m),1.60- 1.87(2H,m),1.89-2.02(3H,m),2.10-2.24(4H,m),2.33-2.52(7H,m),2.69(1H,sep ,J=6.4Hz),2.69-2.81(2H,m),2.87-3.00(2H,m),3.26(2H,ddd,J=20.8,10.4,4.0H z),3.40-3.48(1H,m),3.62-3.71(2H,m),4.04-4.20(1H,m),4.28(1H,d,J=8.4Hz).
[0407] Embodiments 2 to 17:
[0408] As compounds corresponding to the raw material A and raw material B described in Example 1, the compounds of Examples 2 to 17 shown in the following table were prepared in the same manner as in Example 1 using known products in the literature or compounds of reference examples described in the following table.
[0409] [Table 1]
[0410]
[0411] [Table 2]
[0412]
[0413] [Table 3]
[0414]
[0415] [Table 4]
[0416]
[0417] [Table 5]
[0418]
[0419] [Table 6]
[0420]
[0421] The names of the compounds of Examples 2 to 4, Examples 6 to 9, and Examples 11 to 17 are described below.
[0422] Example 2: (3aR, 5S, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-{5-[(1S, 2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0423] Example 3: (1R, 5S, 6R)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-3-azabicyclo[3.1.0]hexane-3-carboxamide;
[0424] Example 4: (1R, 5S, 6S)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-3-azabicyclo[3.1.0]hexane-3-carboxamide;
[0425] Example 6: (3aR, 5R, 6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-methylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0426] Example 7: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-{5-[(1S, 2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-5-methylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0427] Example 8: (3aR, 5R, 6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0428] Example 9: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0429] Example 11: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0430] Example 12: (3aR, 5S, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0431] Example 13: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-methylphenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0432] Example 14: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(2-methylphenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0433] Example 15: (3aR, 5R, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-fluorophenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0434] Example 16: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(3-fluorophenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0435] Example 17: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(2-fluorophenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide.
[0436] The compounds of Example 5 and Example 10 are respectively diastereomeric mixtures containing two different diastereomers. They can also be separated by asymmetric synthesis or chiral chromatography. That is, it can be said that the two diastereomers are substantially synthesized separately.
[0437] [Table 7]
[0438]
[0439] Embodiments 18 to 34:
[0440] As compounds corresponding to the raw material A and raw material B described in Example 1, the compounds of Examples 18 to 34 shown in the following table were prepared in the same manner as in Example 1 using known products in the literature or compounds of reference examples described in the following table.
[0441] [Table 8]
[0442]
[0443] [Table 9]
[0444]
[0445] [Table 10]
[0446]
[0447] [Table 11]
[0448]
[0449] [Table 12]
[0450]
[0451] [Table 13]
[0452]
[0453] The names of the compounds of Examples 18 to 34 are described below.
[0454] Example 18: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0455] Example 19: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(2-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0456] Example 20: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyridin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0457] Example 21: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0458] Example 22: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(3-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0459] Example 23: (3aR, 6aS)-N-{(1R, 6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-methylphenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0460] Example 24: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(3-methylphenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0461] Example 25: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyridin-2-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0462] Example 26: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyrimidin-2-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0463] Example 27: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyridin-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0464] Example 28: (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0465] Example 29: (3aR, 6aS)-N-[(1R, 6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-5-phenylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide;
[0466] Example 30: (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(5-methyl-1,2,4-oxadiazol-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0467] Example 31: (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-5-(5-methyl-1,2,4-oxadiazol-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0468] Example 32: (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-5-(5-methyl-1,2,4-oxadiazol-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0469] Example 33: (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide;
[0470] Example 34: (3aR,6aS)-N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-5-phenylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide.
[0471] Reference Example 1:
[0472] (3aR,5s,6aS)-5-cyanohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (Compound 2) and (3aR,5r,6aS)-5-cyanohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (Compound 3)
[0473] [Chemical formula 25]
[0474]
[0475] To a solution of 331 mg of compound 1 in 6.7 mL of 1,2-dimethoxyethane / 0.67 mL of ethanol, 373 mg of p-toluenesulfonylmethyl isocyanide and 396 mg of potassium tert-butoxide were added at 0° C., and the mixture was stirred at 40° C. for 4 hours. After cooling to room temperature, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: hexane / ethyl acetate) to obtain 80 mg of the title compound 2 and 59.4 mg of the title compound 3.
[0476] Compound 2: LCMS: [M+H] + / Rt(min):237 / 0.89;
[0477] Compound 3: LCMS: [M+H] + / Rt(min):237 / 0.88.
[0478] Reference Example 2:
[0479] (1S,6R,8S)-8-Cyano-3-azabicyclo[4.2.0]octane-3-carboxylic acid tert-butyl ester
[0480] [Chemical formula 26]
[0481]
[0482] Step (i):
[0483] 352 μL of isobutyl chloroformate and 393 μL of triethylamine were added to a 7.8 mL chloroform solution of 600 mg of compound 4 at 0°C and stirred for 2 hours. After that, aqueous ammonia was added to the reaction solution at 0°C, the temperature was raised to room temperature, and after stirring for 1 hour, water was added to the reaction mixture and extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: hexane / ethyl acetate) to obtain 372 mg of compound 5.
[0484] LCMS: [M+H] + / Rt(min):255 / 0.72.
[0485] Step (ii):
[0486] 0.27 mL of trifluoromethanesulfonic anhydride was added to a 6 mL chloroform solution of 364 mg of compound 5 and 0.63 mL of diisopropylethylamine at 0°C and stirred for 1 hour. After that, water was added to the reaction mixture and extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: hexane / ethyl acetate) to obtain 320 mg of the title compound 6.
[0487] LCMS: [M+H] + / Rt(min):237 / 0.93.
[0488] Reference Example 3:
[0489] (3aR,5r,6aS)-5-Cyano-5-methylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylic acid tert-butyl ester
[0490] [Chemical formula 27]
[0491]
[0492] To a solution of lithium diisopropylamide (1.09M n-hexane solution, 16mL) in 8mL THF, 2.05g of compound 2 in 8mL THF was slowly added dropwise at -78°C, and stirred for 1.5 hours after the addition. Next, 2.7mL of iodomethane in 8mL THF was added at -78°C, and the mixture was stirred for 2 hours after warming to 0°C. A 1M aqueous solution of potassium hydrogen sulfate was added to the reaction solution, the mixture was warmed to room temperature, and extracted with hexane. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: hexane / ethyl acetate) to obtain 0.8g of the title compound 7.
[0493] LCMS: [M+H] + / Rt(min):251 / 0.93.
[0494] Reference Example 4:
[0495] (3aR,5s,6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)octahydrocyclopenta[c]pyrrole
[0496] [Chemical formula 28]
[0497]
[0498] Step (i):
[0499] 20 mL of 50% aqueous hydroxylamine solution was added to a 62 mL ethanol solution of 7.3 g of compound 2, and the mixture was stirred at 70°C for 11 hours. After cooling to room temperature, 120 mL of water was added to the reaction mixture, and the mixture was extracted with toluene. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 4.6 g of compound 8.
[0500] LCMS: [M+H] + / Rt(min):270 / 0.52.
[0501] Step (ii):
[0502] Under ice bath, 3.80 mL of triethylamine was slowly added dropwise to a mixture of 1.47 g of compound 8, 0.493 g of cyclopropanecarboxylic acid, 2.28 g of HATU and 11 mL of THF, and stirred at room temperature for 12 hours. 11 mL of ethyl acetate was added to the reaction mixture, and washed with 11 mL of water and 11 mL of saturated brine. The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: hexane / ethyl acetate) to obtain 3.71 g of compound 9.
[0503] LCMS: [M+H] + / Rt(min):338 / 0.82.
[0504] Step (iii):
[0505] A mixture of 400 mg of compound 9, 177 μL of DBU, 2.2 mL of toluene and 0.741 mL of acetonitrile was stirred under heating reflux for 1 hour, cooled to room temperature, washed with water, and the organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: hexane / ethyl acetate) to obtain 106 mg of compound 10.
[0506] LCMS: [M+H] + / Rt(min):320 / 1.04.
[0507] Step (iv):
[0508] 1.6 mL of trifluoroacetic acid was added to a 2.8 mL toluene solution of 880 mg of compound 10, and the mixture was stirred overnight. After that, the reaction solution was concentrated under reduced pressure, and 2.76 mL of toluene / 0.9 mL of acetonitrile and 2.92 g of sodium carbonate were added, and the mixture was stirred for 1 hour. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to obtain 690 mg of the title compound 11.
[0509] LCMS: [M+H] + / Rt(min):220 / 0.39.
[0510] Reference Examples 5 to 11:
[0511] Using carboxylic acid B described in the following table instead of cyclopropanecarboxylic acid in step (ii) of Reference Example 4, Reference Example 5 shown in the following table was synthesized according to the method described in the above Reference Example 4. In addition, using the corresponding raw materials A and carboxylic acid B instead of the raw material (compound 2) in step (i) of Reference Example 4 and the cyclopropanecarboxylic acid in step (ii), the compounds of Reference Examples 6 to 11 shown in the following table were synthesized according to the method described in the above Reference Example 4.
[0512] [Table 14]
[0513]
[0514] The names of the compounds of Reference Examples 5 to 11 are described below.
[0515] Reference Example 5: (3aR, 5s, 6aS)-5-{5-[(1S, 2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}octahydrocyclopenta[c]pyrrole;
[0516] Reference Example 6: (1R,5S,6r)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-3-azabicyclo[3.1.0]hexane monohydrochloride;
[0517] Reference Example 7: (1R,5S,6s)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-3-azabicyclo[3.1.0]hexane monohydrochloride;
[0518] Reference Example 8: (1S,6R,8S)-8-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-3-azabicyclo[4.2.0]octane monohydrochloride;
[0519] Reference Example 9: (3aR, 5r, 6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-methyloctahydrocyclopenta[c]pyrrole;
[0520] Reference Example 10: (3aR, 5r, 6aS)-5-{5-[(1S, 2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-5-methyloctahydrocyclopenta[c]pyrrole;
[0521] Reference Example 11: (3aR, 5r, 6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)octahydrocyclopenta[c]pyrrole.
[0522] Reference Example 12:
[0523] (3aR,5r,6aS)-5-(4-Methylphenyl)octahydrocyclopenta[c]pyrrole
[0524] [Chemical formula 29]
[0525]
[0526] Step (i):
[0527] At room temperature, 149 mg of 4-methylphenylboric acid and 0.456 ml of 2M potassium carbonate aqueous solution and 211 mg of tetrakistriphenylphosphine palladium were added to a solution of 326 mg of compound 12 in 3.2 mL of 1,2-dimethoxyethane, and stirred at 80 ° C for 11 hours. After cooling to room temperature, 10 mL of water was added to the reaction mixture and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: hexane / ethyl acetate) to obtain 139 mg of compound 13.
[0528] LCMS: [M+H] + / Rt(min):300 / 2.313(Method B).
[0529] Step (ii):
[0530] 26.1 mg of palladium hydroxide-activated carbon was added to a solution of 139 mg of compound 13 in 3.9 mL of methanol, and the mixture was stirred at room temperature for 2 hours. After the reaction, the reaction solution was filtered through Celite, and the filtrate was concentrated to obtain 98 mg of compound 14.
[0531] LCMS: [M+H] + / Rt(min):302 / 2.346(Method B).
[0532] Step (iii):
[0533] 0.125 mL of TFA was added to a 0.33 mL chloroform solution of 98 mg of compound 14, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, a 3 M sodium hydroxide aqueous solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 29.5 mg of the title compound 15.
[0534] LCMS: [M+H] + / Rt(min):202 / 1.481(Method B).
[0535] Reference Examples 13 to 16:
[0536] The compounds of Reference Examples 13 to 16 shown in the following table were synthesized according to the method described in Reference Example 12 using the corresponding starting material C in place of 4-methylphenylboronic acid in step (i) of Reference Example 12.
[0537] [Table 15]
[0538]
[0539] Reference Example 13: (3aR, 5r, 6aS)-5-(2-methylphenyl)octahydrocyclopenta[c]pyrrole monohydrochloride;
[0540] Reference Example 14: (3aR, 5r, 6aS)-5-(4-fluorophenyl)octahydrocyclopenta[c]pyrrole monohydrochloride;
[0541] Reference Example 15: (3aR, 5r, 6aS)-5-(3-fluorophenyl)octahydrocyclopenta[c]pyrrole monohydrochloride;
[0542] Reference Example 16: (3aR, 5r, 6aS)-5-(2-Fluorophenyl)octahydrocyclopenta[c]pyrrole monohydrochloride.
[0543] Reference Example 17:
[0544] (3aR,6aS)-2-(2-Fluorophenyl)octahydropyrrolo[3,4-c]pyrrole monohydrochloride
[0545] [Chemical formula 30]
[0546]
[0547] Step (i):
[0548] At room temperature, 309 mg of 1-bromo-2-fluorobenzene and 424 mg of sodium tert-butoxide, 129 mg of tris(dibenzylideneacetone)dipalladium(0), and 42.2 mg of di-tert-butyl 2-biphenylphosphine were added to a 6.8 mL toluene solution of 413 mg of compound 16, and stirred at 90°C for 30 minutes. After cooling to room temperature, water was added to the reaction mixture, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: hexane / ethyl acetate) to obtain 270 mg of compound 17.
[0549] LCMS: [M+H] + / Rt(min):307 / 2.15(Method B).
[0550] Step (ii):
[0551] To a solution of 305 mg of the compound 17 in 4 ml of chloroform was added 1.2 ml of hydrochloric acid (4 M cyclopentylmethyl solution), and the mixture was stirred at room temperature for 2.5 hours. The reaction solution was then concentrated to obtain 287 mg of the title compound 18.
[0552] LCMS: [M+H] + / Rt(min):207 / 1.28(Method B).
[0553] Reference Example 18:
[0554] (3aR,6aS)-2-(3-Fluorophenyl)octahydropyrrolo[3,4-c]pyrrole monohydrochloride
[0555] The compounds of Reference Example 18 shown in the following table were synthesized according to the method described in Reference Example 17 using 1-bromo-3-fluorobenzene instead of 1-bromo-2-fluorobenzene in step (i) of Reference Example 17.
[0556] [Table 16]
[0557]
[0558] Reference Example 19:
[0559] (3aR,5r,6aS)-5-(3-Methylphenyl)octahydrocyclopenta[c]pyrrole monohydrochloride
[0560] The compounds of Reference Example 19 shown in the following table were synthesized according to the method described in Reference Example 12 using 3-methylphenylboronic acid instead of 4-methylphenylboronic acid in step (i) of Reference Example 12.
[0561] [Table 17]
[0562]
[0563] Reference Example 20:
[0564] (3aR,5r,6aS)-5-(Pyridin-2-yl)octahydrocyclopenta[c]pyrrole monohydrochloride
[0565] [Chemical formula 31]
[0566]
[0567] Step (i):
[0568] At room temperature, 2.59 g of pinacol diboronate, 2.51 g of potassium acetate, 278 mg of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), and 189 mg of 1,1'-bis(diphenylphosphino)ferrocene were added to a solution of 3.04 g of compound 12 in 28.4 mL of 1,4-dioxane, and stirred at 80°C for 8 hours. After cooling to room temperature, the reaction mixture was filtered through Celite and washed with ethyl acetate. After the filtrate was concentrated under reduced pressure, the residue was purified by silica gel column chromatography (eluent: hexane / ethyl acetate) to obtain 2.82 g of compound 19.
[0569] LCMS: [M+H] + / Rt(min):672 / 1.158.
[0570] Step (ii):
[0571] At room temperature, 115 mg of 2-bromopyridine, 0.728 ml of 2M potassium carbonate aqueous solution, and 168 mg of tetrakistriphenylphosphine palladium were added to a solution of 293 mg of compound 19 in 3.6 mL of 1,2-dimethoxyethane, and the mixture was stirred at 80° C. for 2 hours. After cooling to room temperature, the reaction mixture was purified by silica gel column chromatography (eluent: hexane / ethyl acetate) to obtain 130 mg of compound 20.
[0572] LCMS: [M+H] + / Rt(min):287 / 1.46(Method B).
[0573] Step (iii):
[0574] Using compound 20, compound 21 was obtained by the same method as in step (iii) of reference example 12.
[0575] LCMS: [M+H] + / Rt(min):289 / 1.49(Method B).
[0576] Step (iv):
[0577] Using compound 21, the title compound 22 was obtained in the same manner as in step (ii) of reference example 17.
[0578] LCMS: [M+H] + / Rt(min):189 / 0.778(Method B).
[0579] Reference Examples 21 and 22:
[0580] The compounds of Reference Examples 21 and 22 shown in the following table were synthesized according to the method described in Reference Example 19 using the corresponding starting material D in place of 2-bromopyridine in step (ii) of Reference Example 19.
[0581] [Table 18]
[0582]
[0583] The names of the compounds of Reference Examples 21 and 22 are described below.
[0584] Reference Example 21: (3aR, 5r, 6aS)-5-(pyrimidin-2-yl)octahydrocyclopenta[c]pyrrole monohydrochloride;
[0585] Reference Example 22: (3aR, 5r, 6aS)-5-(Pyridin-3-yl)octahydrocyclopenta[c]pyrrole monohydrochloride.
[0586] Reference Example 23:
[0587] (3aR,5r,6aS)-5-(5-methyl-1,2,4-oxadiazol-3-yl)octahydrocyclopenta[c]pyrrole monohydrochloride
[0588] The compound of Reference Example 23 shown in the following table was synthesized according to the method described in Reference Example 4 by using the compound of Reference Example 1 instead of the raw material (Compound 2) in step (i) of Reference Example 4 and using acetyl chloride instead of cyclopropanecarboxylic acid and HATU in step (ii).
[0589] [Table 19]
[0590]
[0591] Test Example 1: Determination of orexin type 2 receptor agonist activity
[0592] Human orexin type 2 receptor and apoaequorin were overexpressed in CHO cells, and the excitability was evaluated using the amount of calcium that flowed into the cells under ligand stimulation as an index. The overexpressed cells were seeded at 2,000 cells / well in a 384-well plate and cultured for 16 to 22 hours. After the plate was returned to room temperature, coelenterazine hcp (final concentration: 1 μM) was added, and after standing at room temperature for 2 hours, orexin A (Peptide Research Institute, Inc., Lot. 671009) or the test compound was added, and the luminescence of the cells was measured using FDSS7000 (manufactured by Hamamatsu Photonics). It should be noted that orexin A and the test compound were dissolved in DMSO (final concentration 0.1%) and diluted with a buffer (Hanks, 20 mM HEPES, 0.1% BSA). The luminescence value when treated with orexin A (100 pM) was taken as 100%, and the orexin type 2 receptor agonism of the test compound was calculated as its relative value.
[0593] Test results:
[0594] The compounds obtained in the examples were tested for orexin type 2 receptor agonism, and it was observed that the compounds of the present invention exhibited agonist effects on orexin type 2 receptor. The relative values of orexin type 2 receptor agonism of the compounds obtained in the examples at 10 μM are shown in the following table, with the luminescence value when orexin A (100 pM) was treated as 100%.
[0595] [Table 20]
[0596] Example Excitability (%) Example Excitability (%) 1 375 12 492 2 275 13 466 3 217 14 446 4 15 15 511 5 79 16 491 6 282 17 315 7 328 8 423 9 424 10 450 11 477
[0597] Test Example 2: Determination of orexin type 2 receptor agonist activity
[0598] Human orexin type 2 receptor and apoaequorin were overexpressed in CHO cells, and the excitability was evaluated using the amount of calcium that flowed into the cells under ligand stimulation as an index. The overexpressed cells were seeded at 2,000 cells / well in a 384-well plate and cultured for 16 to 22 hours. After the plate was returned to room temperature, coelenterazine hcp (final concentration: 1 μM) was added, and after standing at room temperature for 2 hours, orexin A (Peptide Research Institute Co., Ltd., Lot. 711101) or the test compound was added, and the luminescence of the cells was measured using FDSS7000 (manufactured by Hamamatsu Photonics Co., Ltd.). It should be noted that orexin A and the test compound were dissolved in DMSO (final concentration 0.1%) and diluted with a buffer (Hanks, 20 mM HEPES, 0.1% BSA). The luminescence value when treated with orexin A (100 pM) was taken as 100%, and the orexin type 2 receptor agonism of the test compound was calculated as its relative value.
[0599] Test results:
[0600] The compounds obtained in the examples were tested for orexin type 2 receptor agonism, and it was observed that the compounds of the present invention exhibited agonist effects on orexin type 2 receptor. The relative values of orexin type 2 receptor agonism of the compounds obtained in the examples at 10 μM are shown in the following table, with the luminescence value when orexin A (100 pM) was treated as 100%.
[0601] [Table 21]
[0602] Example Excitability (%) Example Excitability (%) 18 374 27 348 19 390 28 400 20 345 29 393 21 368 30 374 22 399 31 252 23 404 32 345 24 414 33 343 25 396 34 341 26 345
[0603] Industrial Applicability
[0604] The compound of the present invention exhibits strong agonist activity on orexin type 2 receptors and is useful as a therapeutic or preventive drug for diseases such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome accompanied by narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, and hypersomnia associated with Lewy body dementia.
Claims
1. A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, [Chemical formula 1] In the formula, R 1 and R 2 each independently represents a hydrogen atom, a halogen atom, a cyano group, -(=O)NR 3 R 4 , carboxyl, -(C=O)OR 5 , C that can be replaced 1-4 Alkyl or substituted C 1-4 Alkoxy, in addition, R 1 and R 2 If chemically possible, they can bond to the same carbon atom. 1 and R 2 When the carbon atoms on the ring are bonded to different carbon atoms, they can be bonded to each other through C 1-6 Alkylene groups are bonded to form condensed rings or bridged rings; R 3 and R 4 Each independently represents a hydrogen atom or a substitutable C 1-4 alkyl; R 5 Indicates a replaceable C 1-4 alkyl; -L 1 -Ring G represents -Ring G, -CH2-Ring G (the CH2 may be replaced by one or more identical or different C 1-6 Alkyl substituted), -NR 6 -Ring G, -C(=O)-Ring G, -OC(=O)-Ring G, -SO-Ring G, -SO2-Ring G, -S-Ring G or -O-Ring G; R 6 Represents a hydrogen atom or a replaceable C 1-4 alkyl; n is an integer of 1 or 2; Ring G represents a C which may be substituted 6-10 Aromatic carbocyclic group, 5-10 membered aromatic heterocyclic group which may be substituted, C 3-6 A saturated carbocyclic group or a 4- to 10-membered saturated heterocyclic group which may be substituted; A 1 represents an oxygen atom or a sulfur atom; A 2 represents an oxygen atom or -NH-; j, k, l and m are each independently an integer of 0, 1 or 2; The dashed line represents a single bond or a double bond; X stands for -CR 7 -, nitrogen atom or carbon atom; R 7 represents a hydrogen atom, a hydroxyl group, a halogen atom, a cyano group, or a substituted C 1-4 alkyl; Ring E represents the following formula (1a-1), (1a-2) or (1a-3): [Chemical formula 2] In the formula, X 1 ~X 8 Each independently represents a nitrogen atom or -CR a4 -; Q 1 and Q 2 Represents oxygen atom or -NR a5 -; R a1 ~R a5 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), cyano, C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl, C 1-4 substituted with an alkoxy group) or a 5- to 10-membered aromatic heterocyclic group, and R a2 and R a3 If chemically possible, they can be bonded to the same carbon atom; In X 1 and X 3 All CR a4 In the case of 2 R a4 Together with the carbon atoms to which they are bonded, they can form 1 , X 2 and X 3 The 5-membered ring is condensed to form a 6-membered carbon ring.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 ~R 7 The "C 1-4 The substituents in the "alkyl" are each independently 1 or 2 or more of the same or different halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl, "C 1-4 The substituents in the "alkoxy" are each independently 1 or 2 or more halogen atoms, hydroxyl groups or C 3-7 Cycloalkyl, Ring G C 6-10 Aromatic carbocyclic group, 5-10 membered aromatic heterocyclic group, C 3-6 The substituents which may be substituted in the saturated carbocyclic group and the 4- to 10-membered saturated heterocyclic group are each independently selected from halogen atoms, C 1-6 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substituted), C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-7 Cycloalkyl substituted), C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 3-7 Cycloalkyl substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-7 Cycloalkyl substituted) and C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-7 cycloalkyl) or, if there are multiple substituents, two of them may be C 1-6 The alkylene groups are bonded to form any chemically possible bicyclic structure in a fused ring, a spiro ring or a bridged ring.
3. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein: R 1 ~R 7 The "C 1-4 The substituents in the "alkyl" are each independently 1 or 2 or more halogen atoms or C 1-4 Alkoxy, "C 1-4 The substituents in the "alkoxy" group are each independently 1 or 2 or more halogen atoms which are the same or different, Ring G C 6-10 Aromatic carbocyclic group, 5-10 membered aromatic heterocyclic group, C 3-6 The substituents which may be substituted in the saturated carbocyclic group and the 4- to 10-membered saturated heterocyclic group are each independently selected from halogen atoms, C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted), C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted with 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms which are the same or different), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted) and C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 substituted with alkoxy) or, in the case of having multiple substituents, two of which may be C 1-6 The alkylene groups are bonded to form any chemically possible bicyclic structure in a fused ring, a spiro ring or a bridged ring.
4. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein Ring E represents the following formula (1a-1-1), (1a-2-1), (1a-3-1), (1a-3-2), (1a-3-3) or (1a-3-4): [Chemical formula 3] In the formula, X 1 ~X 5 Each independently represents a nitrogen atom or -CR a4 -; R a1 ~R a4 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), cyano, C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 substituted with alkoxy) or a 5- to 10-membered aromatic heterocyclic group, R a2 and R a3 If chemically possible, they can be bonded to the same carbon atom; 1 and X 3 All -CR a4 - In the case of 2 R a4 Together with the carbon atoms to which they are bonded, they can form 1 , X 2 and X 3 The 5-membered ring is condensed to form a 6-membered carbon ring.
5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein Ring G represents the following formula (1b-1) or (1b-2): [Chemical formula 4] In the formula, W 1 and W 3 Each independently represents a nitrogen atom or -CR b3 -; W 2 and W 4 Each independently represents -NR b4 -, oxygen atom or -CR b5 R b6 -; R b1 ~R b6 Each independently represents a hydrogen atom, -N(R b7 )R b8 , C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms, C 3-6 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkyl substitution, the C 1-4 The alkyl group may be substituted with a halogen atom) or C 1-4 Alkoxy substituted), C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted with 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms which are the same or different), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted), in addition, R b1 and R b2 Can bond to the same carbon atom if chemically possible; Here, R b1 and R b2 Available via C 1-6 Alkylene groups are bonded to form any chemically possible bicyclic structure in a fused ring, a spiro ring or a bridged ring; R b7 and R b8 Each independently represents a hydrogen atom, C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms, C 1-4 Alkoxy, C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkyl substitution, the C 1-4 The alkyl group may be substituted with a halogen atom) or a 5- to 10-membered aromatic heterocyclic group), a 5- to 10-membered aromatic heterocyclic group (the aromatic heterocyclic group may be substituted with 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), Here, in R b1 ~R b6 -N(R b7 )R b8 In the case of R b7 and R b8 They may be combined with the nitrogen atom to which they are bonded to form a 3- to 7-membered nitrogen-containing saturated heterocyclic ring.
6. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof, which is represented by formula (2): [Chemical formula 5] In the formula, R 1 and R 2 Each independently represents a hydrogen atom, a halogen atom, a C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substituted) or C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 3-7 Cycloalkyl substitution); -L 1 -Ring G represents -Ring G, -CH2-Ring G (the CH2 may be replaced by one or more identical or different C 1-6 Alkyl substituted), -NR 6 -Ring G, -C(=O)-Ring G, -OC(=O)-Ring G, -SO-Ring G, -SO2-Ring G, -S-Ring G or -O-Ring G; R 6 Each independently represents a hydrogen atom or a C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution); Ring G represents the following formula (1b-1) or (1b-2): [Chemical formula 6] In the formula, W 1 and W 3 Each independently represents a nitrogen atom or -CR b3 -; W 2 and W 4 Each independently represents -NR b4 -, oxygen atom or -CR b5 R b6 -; R b1 ~R b6 Each independently represents a hydrogen atom, -N(R b7 )R b8 , C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms, C 3-6 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkyl substitution, the C 1-4 The alkyl group may be substituted with a halogen atom) or C 1-4 Alkoxy substituted), C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted with 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms which are the same or different), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted), in addition, R b1 and R b2 Can bond to the same carbon atom if chemically possible; Here, R b1 and R b2 Available via C 1-6 Alkylene groups are bonded to form any chemically possible bicyclic structure in a fused ring, a spiro ring or a bridged ring; R b7 and R b8 Each independently represents a hydrogen atom, C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms, C 1-4 Alkoxy, C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkyl substitution, the C 1-4 The alkyl group may be substituted with a halogen atom) or a 5- to 10-membered aromatic heterocyclic group), a 5- to 10-membered aromatic heterocyclic group (the aromatic heterocyclic group may be substituted with 1 or 2 or more halogen atoms, C 1-4 Alkyl or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), Here, in R b1 ~R b6 -N(R b7 )R b8 In the case of R b7 and R b8 They can become one with the nitrogen atom to which they are bonded to form a 3-7 membered nitrogen-containing saturated heterocyclic ring; A 1 represents an oxygen atom or a sulfur atom; j, k, l and m are each independently an integer of 0, 1 or 2; The dashed line represents a single bond or a double bond; X stands for -CR 7 -, nitrogen atom or carbon atom; R 7 represents a hydrogen atom, a hydroxyl group, a halogen atom, a cyano group or a C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution); Ring E represents the following formula (1a-1-1), (1a-2-1), (1a-3-1), (1a-3-2), (1a-3-3) or (1a-3-4): [Chemical formula 7] In the formula, X 1 ~X 5 Each independently represents a nitrogen atom or -CR a4 -; R a1 ~R a4 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), cyano, C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 substituted with an alkoxy group) or a 5- to 10-membered aromatic heterocyclic group, and R a2 and R a3 If chemically possible, they can be bonded to the same carbon atom; In X 1 and X 3 All -CR a4 - In the case of 2 R a4 Together with the carbon atoms to which they are bonded, they can form 1 , X 2 and X 3 The 5-membered ring is condensed to form a 6-membered carbon ring.
7. The compound according to claim 6 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Each independently represents a hydrogen atom, a halogen atom, a C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution); L 1 represents a single bond or an oxygen atom; Ring G represents the following formula (1b-1-1), (1b-2-1), (1b-1-2) or (1b-2-2): [Chemical formula 8] In the formula, R b4 , R b7 and R b8 Each independently represents a hydrogen atom or a C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 alkoxy substituted).
8. The compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, which is represented by formula (3): [Chemical formula 9] In the formula, L 1 represents a single bond or an oxygen atom; Ring G represents the following formula (1b-1-1), (1b-2-1), (1b-1-2) or (1b-2-2): [Chemical formula 10] In the formula, R b4 , R b7 and R b8 Each independently represents a hydrogen atom or a C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted); j, k, l and m are each independently an integer of 0, 1 or 2; The dashed line represents a single bond or a double bond; X stands for -CR 7 -, nitrogen atom or carbon atom; R 7 represents a hydrogen atom, a hydroxyl group, a halogen atom, a cyano group or a C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution); Ring E represents the following formula (1a-1-1), (1a-2-1), (1a-3-1), (1a-3-2), (1a-3-3) or (1a-3-4): [Chemical formula 11] In the formula, X 1 ~X 5 Each independently represents a nitrogen atom or -CR a4 -; R a1 ~R a4 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), cyano, C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 substituted with an alkoxy group) or a 5- to 10-membered aromatic heterocyclic group, and R a2 and R a3 If chemically possible, they can be bonded to the same carbon atom; In X 1 and X 3 All -CR a4 - In the case of 2 R a4 Together with the carbon atoms to which they are bonded, they can form 1 , X 2 and X 3 The 5-membered ring is condensed to form a 6-membered carbon ring.
9. The compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, which is represented by formula (4): [Chemical formula 12] In the formula, L 1 represents a single bond or an oxygen atom; Ring G represents the following formula (1b-1-1), (1b-2-1), (1b-1-2) or (1b-2-2): [Chemical formula 13] In the formula, R b4 , R b7 and R b8 Each independently represents a hydrogen atom or a C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted); The dashed line represents a single bond or a double bond; X stands for -CR 7 -, nitrogen atom or carbon atom; R 7 Represents a hydrogen atom or C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution); Ring E represents the following formula (1a-1-1), (1a-2-1), (1a-3-1), (1a-3-2), (1a-3-3) or (1a-3-4): [Chemical formula 14] In the formula, X 1 ~X 5 Each independently represents a nitrogen atom or -CR a4 -; R a1 ~R a4 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 6-10 Aromatic carbocyclic group (the C 6-10 The aromatic carbocyclic group may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted), cyano, C 1-4 Alkoxy (the alkoxy may be substituted by 1 or 2 or more halogen atoms, hydroxyl groups or C 1-4 Alkoxy substituted), C 3-7 Cycloalkoxy (the cycloalkoxy may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 substituted with alkoxy) or a 5- to 10-membered aromatic heterocyclic group, R a2 and R a3 If chemically possible, they can be bonded to the same carbon atom; In X 1 and X 3 All -CR a4 - In the case of 2 R a4 Together with the carbon atoms to which they are bonded, they can form 1 , X 2 and X 3 The 5-membered ring is condensed to form a 6-membered carbon ring.
10. The compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein Ring E represents the above formula (1a-2-1) or (1a-3-1): In the formula, X 4 ~X 5 Each independently represents a nitrogen atom or -CR a4 -; R a1 ~R a4 Each independently (in the presence of multiple CR a4 In the case of a4 also each independently) represents a hydrogen atom, a halogen atom, C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted), C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 Alkoxy substituted) or C 1-4 Alkoxy group (the alkoxy group may be substituted by 1 or 2 or more halogen atoms which are the same or different).
11. The compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein Ring E represents the following formula (1a-2-2) or (1a-3-1): [Chemical formula 15] In the formula, R a1 ~R a3 Each independently represents a hydrogen atom, a halogen atom, a C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 alkoxy substituted).
12. The compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, which is represented by formula (5): [Chemical formula 16] In the formula, L 1 represents a single bond or an oxygen atom; Ring G represents the following formula (1b-1-1) or (1b-2-1): [Chemical formula 17] In the formula, R b4 Represents a hydrogen atom or C 1-6 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted); R 7 Represents a hydrogen atom or C 1-4 Alkyl (the alkyl group may be 1 or 2 or more halogen atoms, hydroxyl groups, C 1-4 Alkoxy or C 3-7 Cycloalkyl substitution); Ring E represents the following formula (1a-2-2) or (1a-3-1): [Chemical formula 18] In the formula, R a1 ~R a3 Each independently represents a hydrogen atom, a halogen atom, a C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 Alkoxy substituted) or C 3-7 Cycloalkyl (the cycloalkyl may be substituted by 1 or 2 or more identical or different halogen atoms, hydroxyl groups, C 1-4 Alkyl or C 1-4 alkoxy substituted).
13. The compound according to claim 12 or a pharmaceutically acceptable salt thereof, wherein Ring G represents the above formula (1b-1-1), and R b4 is C which may be substituted by 1 or 2 or more halogen atoms which are the same or different 1-4 alkyl.
14. The compound according to claim 12 or a pharmaceutically acceptable salt thereof, wherein Ring G represents the above formula (1b-2-1), and R b4 Represents a hydrogen atom or C 1-4 Alkyl (the alkyl group may be substituted by 1 or 2 or more halogen atoms or C 1-4 alkoxy substituted).
15. The compound according to claim 12 or a pharmaceutically acceptable salt thereof, wherein R 7 A hydrogen atom.
16. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, which is selected from the following compounds: (3aR,5S,6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5S,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (1R,5S,6R)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-3-azabicyclo[3.1.0]hexane-3-carboxamide; (1R,5S,6S)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-3-azabicyclo[3.1.0]hexane-3-carboxamide; (3aR,5R,6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-methylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-5-methylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide; (3aR,5S,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-methylphenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(2-methylphenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-fluorophenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(3-fluorophenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(2-fluorophenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (1S,6R,8S)-8-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-3-azabicyclo[4.2.0]octane-3-carboxamide; (1R,6S,8R)-8-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-3-azabicyclo[4.2.0]octane-3-carboxamide; (3aS,6aR)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenyl-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-phenyl-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(2-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyridin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(3-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(4-methylphenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(3-methylphenyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyridin-2-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyrimidin-2-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(pyridin-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-5-phenylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-5-(5-methyl-1,2,4-oxadiazol-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-5-(5-methyl-1,2,4-oxadiazol-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-5-(5-methyl-1,2,4-oxadiazol-3-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,5R,6aS)-N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-5-phenylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-5-phenylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide.
17. A pharmaceutical composition comprising the compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.
18. A pharmaceutical composition comprising a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof, for use in the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy bodies.
19. A therapeutic agent for a disease associated with orexin type 2 receptor, comprising the compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.
20. A therapeutic agent for the following diseases, comprising a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof: narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, hypersomnia associated with dementia with Lewy bodies, hypersomnia syndrome with excessive daytime sleepiness (e.g., Kleine-Levin syndrome, major depression associated with hypersomnia, dementia with Lewy bodies, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, cerebral contusion, cerebral infarction, brain tumor, muscular atrophy, multiple sclerosis, acute disseminated cerebrospinal fluid Myelitis, Guillain-Barré syndrome, Rasmussen encephalitis, Wernicke encephalitis, limbic encephalitis, Hashimoto's encephalitis), lethargy, loss of consciousness, obesity (e.g., malignant mast cells, exogenous obesity, hyperpancreatic obesity, protoplasmic obesity, pituitary obesity, hypoprotoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, pediatric obesity, upper body obesity, dietary obesity, hyposexual obesity, systemic mastocytosis, simple obesity, central obesity), insulin resistance syndrome, Alzheimer's disease, impaired consciousness such as lethargy, side effects or complications caused by anesthesia, sleep disorders, sleep problems, insomnia, intermittent sleep, nocturnal clonic muscle spasms, REM sleep sleep disturbance, jet lag, jet lag syndrome, sleep disorders in shift workers, abnormal sleep, night terrors, depression, major depression, sleepwalking, enuresis, sleep disorders, Alzheimer's twilight syndrome, diseases related to circadian rhythm, fibromyalgia, symptoms caused by poor sleep quality, overeating, compulsive eating disorders, obesity-related diseases, hypertension, diabetes, increased plasma insulin concentration and insulin resistance, hyperlipoproteinemia, hyperlipidemia, endometrial cancer, breast cancer, prostate cancer, colon cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, cholelithiasis, heart disease, abnormal heart beat, arrhythmia, myocardial infarction, congestive heart failure, heart failure, coronary heart disease, cardiovascular disease, sudden death, Polycystic ovary disease, craniopharyngioma, Prader-Willi syndrome, Fröhlich syndrome, growth hormone deficiency, normal variant short stature, Turner syndrome, childhood acute lymphoblastic leukemia, syndrome X, reproductive hormone abnormalities, reduced fertility, infertility, male hypogonadism, female male-type hirsutism and other sexual and reproductive dysfunctions, fetal defects related to maternal obesity, gastroesophageal reflux and other gastrointestinal motility diseases related to obesity, obesity hypoventilation syndrome (Pickwick syndrome), respiratory diseases such as dyspnea, systemic inflammation of the vascular system and other inflammations, arteriosclerosis, hypercholesterolemia, hyperuricemia, low back pain, gallbladder disease, gout, kidney cancer, reduce the risk of left ventricular hypertrophy and other secondary consequences of obesity,Migraine, headache, neuropathic pain, Parkinson's disease, psychosis, schizophrenia, facial flushing, night sweats, genital / urinary system diseases, diseases related to sexual function or fertility, depression, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymia, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, anxiety disorder, acute neurological and psychiatric disorders such as brain defects after heart bypass surgery and transplantation, stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic nerve damage, Huntington's disease, myopathy Atrophic lateral sclerosis, multiple sclerosis, eye damage, retinal disease, cognitive impairment, muscle spasms, tremors, epilepsy, disorders related to muscle wasting, delirium, amnesia, cognitive decline associated with age, schizoaffective disorder, paranoia, drug dependence, movement disorders, chronic fatigue syndrome, fatigue, drug-induced parkinsonism, Tourette syndrome, chorea, muscle tremors, tics, restless legs syndrome, dystonia, movement disorders, attention deficit hyperactivity disorder (ADHD), behavioral disorders, urinary incontinence, withdrawal symptoms, trigeminal neuralgia, hearing loss, tinnitus, nerve damage, retinal disease, macular degeneration, vomiting, brain edema, pain, bone pain, joint pain, toothache, cataplexy, or traumatic brain injury.
21. A therapeutic agent for narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy bodies, comprising a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.
22. A therapeutic agent for narcolepsy, comprising the compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.
23. A therapeutic agent for idiopathic hypersomnia, comprising the compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.
24. A method for treating a disease associated with orexin type 2 receptor, comprising: A therapeutically effective amount of the compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof is administered to a patient in need of treatment.
25. A method for treating narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy bodies, comprising: A therapeutically effective amount of the compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof is administered to a patient in need of treatment. 26 . The compound or pharmaceutically acceptable salt thereof according to claim 1 , for use in the treatment and / or prevention of a disease associated with orexin type 2 receptor.
27. A compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof, for use in the treatment and / or prevention of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy bodies.
28. Use of the compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for a disease associated with orexin type 2 receptor.
29. Use of a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy bodies.
30. A drug comprising a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof in combination with at least one drug selected from the group consisting of drugs for treating diseases classified as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, or drugs for treating Parkinson's disease or dementia with Lewy bodies.
31. A drug comprising a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof, the drug being used in combination with at least one drug selected from drugs for treating diseases classified as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome with narcolepsy-like symptoms, or drugs for treating Parkinson's disease or dementia with Lewy bodies for treating a disease associated with orexin type 2 receptor.
Citation Information
Patent Citations
Substituted piperidine compound and use thereof
WO2017135306A1
Cycloalkyl urea derivative
WO2021107023A1
